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ABSTRACT 
Carcinoma of the cervix is the most common female genital cancer in 
Developing countries. About 500,000 women acquire the disease and about 
75% are from developing countries annually. In Sudan cancer of the cervix is 
the second most killer cancer, next to breast cancer by 18%. Human papilloma 
virus infection among others is incriminated mainly in the development of 
cervical carcinoma.  
The objective is to evaluate the types of screening methods available in the 
Sudan. A cross-sectional study has been designed to evaluate the validity of Pap 
smear, Colposcopy and visual inspection of cervix using acetic acid in the 
diagnosis of cervical lesions in women of reproductive age. The study has been 
carried at screening centers in Khartoum which includes 31 patients.   
The main results indicate that most cases of cervical malignancies are common 
between the ages 31-40 by 45.2%. Hormonal drugs and /or contraceptives are 
related to the genesis of cervical cancer at a frequency of 45.2%. Vaginal 
discharge is the main symptom by 83.9% for cervical malignancies. Cervical 
ectopy is the main colposcopy finding by 66%. CIN I is found to be the most 
frequent cervical condition by 16.1%. Results of Visual Inspection Using 
Aceto-Acetic Acid (VIA) according to the nature of reaction showed VIA is 
93.5% positive. 
In conclusion, visual inspection using 5 % acetic acid is found to be more 
sensitive and has a higher accuracy as compared to pap smear. Screening using 
VIA has been shown to be effective in screening for the cervical cancer with a 
sensitivity and specificity of 93.5% and 64%, respectively. I therefore 
recommend that VIA might hold the key to effective screening method in low 
resource areas of the Sudan, achieved by its high negative predictive value. 
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 ﺨﻼﺼﺔ ﺍﻟﺭﺴﺎﻟﺔ
 
 
 .ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻫﻭ ﺍﻻﻜﺜﺭ  ﻤﻥ ﺒﻴﻥ ﺴﺭﻁﺎﻥ ﺍﻟﺠﻬﺎﺯ ﺍﻟﺘﻨﺎﺴﻠﻲ ﻋﻨﺩ ﺍﻟﻤﺭﺍﺓ  ﻓﻲ ﺍﻻﻗﻁﺎﺭ  ﺍﻟﻨﺎﻤﻴﺔ
ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ    .ﺘﻭﺠﺩ ﻓﻲ ﺍﻻﻗﻁﺎﺭ ﺍﻟﻨﺎﻤﻴﺔ% 57ﺍﺼﺎﺒﺔ  ﺴﻨﻭﻴﺎ ﻤﻨﻬﺎ  000.005ﺘﻘﺩﺭ ﺍﻻﺼﺒﺎﺒﺎﺕ  ﺒـ
ﻭﺱ ﺍﻟﻭﺭﻡ ﻓﻴﺭ ﻴﻠﻌﺏ .%81ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻴﻌﺘﺒﺭ ﺍﻟﺜﺎﻨﻲ ﺒﻌﺩ  ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻱ ﺒﻨﺴﺒﺔ 
 ﻓﻲ ﺘﻁﻭﺭ ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻜﺒﻴﺭﺍ ﺃﺨﺭﻯ ﺃﺴﺎﺴﺎ ﻋﻮاﻣﻞﻤﻥ ﺒﻴﻥ  (VPH)ﺍﻟﺤﻠﻴﻤﻲ
ﻟﻤﻘﺎﺭﻨﺔ  ﻭﺴﺎﺌل ﺍﻟﻤﻭﺠﺎﺕ   ﻤﺴﺘﻌﺭﻀﺔ ﻤﺼﻤﻤﺔ ﻟﺘﻘﻴﻴﻡ ﺼﻼﺤﻴﺔ ﻤﺴﺤﺔ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﺍﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ 
، ﻤﻨﻅﺎﺭ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﺜﻡ ﺍﻟﺘﻘﻴﻡ  ﺍﻟﻨﻅﺭﻱ  ﻟﻌﻨﻕ ﺍﻟﺭﺤﻡ ﺒﻌﺩ (PAP)ﺍﻟﻤﺨﺘﻠﻔﺔ  ﻭﺍﻟﺘﻘﻴﻴﻡ ﻓﻌﺎﻟﻴﺔ  ﻤﺜل ﺒﺎﺏ 
 13ﺍﺠﺭﻴﺕ ﺍﻟﺩﺍﺭﺴﺔ  ﻋﻨﺩ ﺍﻟﻨﺴﺎﺀ ﻤﻥ ﻓﺘﺭﺓ  ﺍﻟﺨﺼﻭﺒﺔ ﻓﻲ ﺍﻟﺨﺭﻁﻭﻡ ﻋﻠﻲ .  ﺤﺎﻤﺽ ﺍﻟﺨﻠﻴﻙ ﻭﻀﻊ ﺼﺒﻐﺔ
  . ﻤﺭﻴﻀﺔ 
ﺴﻨﺔ ﻭﺍﻟﻨﺴﺒﺔ   04-13ﺍﻅﻬﺭﺕ ﻨﺘﺎﺌﺞ ﺍﻟﻔﺤﺹ ﺍﻥ ﺤﺎﻻﺕ  ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﺍﻜﺜﺭﻫﺎ  ﺒﻴﻥ ﺍﻻﻋﻤﺎﺭ 
ﻫﻨﺎﻙ ﻋﻼﻗﺔ ﻟﻨﺸﺎﺓ ﺴﺭﻁﺎﻥ ﻋﻨﻕ ﺍﻟﺭﺤﻡ ﻋﻨﺩ ﺘﻌﺎﻁﻲ  ﺍﻟﻬﻭﺭﻤﻭﻨﺎﺕ  ﺍﻟﻨﺴﺎﺌﻴﺔ ﻭﻫﻭﺭﻤﻭﻥ %. 2.54ﺍﻟﻤﺌﻭﻴﺔ 
ﻤﻥ ﺍﻟﻌﺭﺽ ﺭﺌﻴﺴﻲ ، ﻭﺍﺤﻤﺭﺍﺭ  ﻋﻨﻕ ﺍﻟﺭﺤﻡ  % 9.38ﺍﻻﻓﺭﺍﺯ ﺍﻟﻤﻬﺒﻠﻰ ﻴﻭﺠﺩ ﻓﻲ . ﻭﺴﺎﺌل ﻤﻨﻊ ﺍﻟﺤﻤل
ﺍﺴﺘﻌﻤﺎل %.  1.61ﺘﺸﺎﻫﺩ ﺒﻨﺴﺒﺔ ( 1.NIC)ﻭﺍﻟﺘﻐﻴﺭﺍﺕ  ﺍﻻﻭﻟﻴﺔ  ﺍﻟﻭﺭﻤﻴﺔ % 66ﻴﺸﺎﻫﺩ ﺒﺎﻟﻤﻨﻅﺎﺭ  ﻋﻨﺩ  
  .  ﻜﺤﺎﻻﺕ  ﺍﻴﺠﺎﺒﻴﺔ % 5.39ﺍﻟﻤﻨﻅﺎﺭ  ﻤﻊ ﺤﺎﻤﺽ ﺍﻟﺨﻠﻴﻙ ﻴﻔﺼﺢ  ﻋﻥ 
ﻤﺤﻠﻭل  ﺤﺎﻤﺽ  ﺍﻟﺨﻠﻴﻙ  ﻴﻤﻜﻥ  ﺍﻥ ﻴﻅﻬﺭ ﺍﻴﺠﺎﺒﻴﺔ  ﻋﺎﻟﻴﺔ ﻓﻲ  %  5ﺍﻟﻔﺤﺹ ﺒﺎﻟﻤﻨﻅﺎﺭ  ﺒﻌﺩ ﻭﻀﻊ 
  .ﺒﺎﻟﺘﻭﺍﻟﻲ %  46ﻭ % 5.39ﺘﻌﺎﺩل  ﻭﺨﺼﻭﺼﻴﺔﻤﻭﻀﻊ ﺍﻻﺼﺎﺒﺔ  ، ﻨﺴﺒﺔ ﺍﻟﺤﺴﺎﺴﻴﺔ 
ﺍﻋﺘﻤﺎﺩ ﺍﻟﻔﺤﺹ ﺒﺎﻟﻤﻨﻅﺎﺭ  ﻤﻊ ﺍﺴﺘﻌﻤﺎل  ﺤﺎﻤﺽ ﺍﻟﺨﻠﻴﻙ  ﻟﺘﺤﺩﻴﺩ ﻤﻭﻗﻊ ﺍﻻﺼﺎﺒﺔ ﻭﺒﻌﺩﻫﺎ ﺍﺨﺫ : ﺍﻟﺘﻭﺼﻴﺔ
ﻗﺩ ﺘﺤﻤل ﻤﻔﺘﺎﺡ  (AIV)ﻭﻟﺫﻟﻙ ﺃﻭﺼﻲ ﺒﺄﻥ  .ﻥ ﺍﻟﻤﺨﺘﻠﻔﺔﻓﻲ ﻨﻭﺍﺤﻲ ﺍﻟﺴﻭﺩﺍ( PAP)ﺍﻟﻌﻴﻨﺔ ﻭﺼﻴﻔﻬﺎ ﺒﺎﻟﺒﺎﺏ 
ﺤﻘﻘﺕ ﻤﻥ ﺤﻴﺙ ﺍﻟﻘﻴﻤﺔ  ، ﺍﻟﺘﻰﺍﻟﺴﻭﺩﺍﻥ ﻓﻰ ﻁﺭﻴﻘﺔ ﺍﻟﻔﺭﺯ ﻓﻌﺎﻟﺔ ﻓﻲ ﺍﻟﻤﻨﺎﻁﻕ ﺫﺍﺕ ﺍﻟﻤﻭﺍﺭﺩ ﺍﻟﻤﻨﺨﻔﻀﺔ
  . ﺍﻟﺘﻨﺒﺅﻴﺔ ﺍﻟﺴﻠﺒﻴﺔ ﺍﻟﻌﺎﻟﻴﺔ
  ___________________________________________________________ 
  . اﻟﺮﺣﻢ ﺗﻘﻴﻴﻢ ﺗﻘﻨﻴﺎت اﻟﻔﺤﺺ ﻟﺘﺸﺨﻴﺺ ﺳﺮﻃﺎن ﻋﻨﻖ
  . 0102، ﺳﺮﻳﺎﻧﻮ اوﻣﻮﺟﻮ اﺗﺎرااﻟﺪآﺘﻮر أوروﻣﻮ ﻓﺮاﻧﺴﻴﺲ 
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CHAPTER ONE  
INTRODUCTION AND LITERATURE REVIEW  
1. Introduction: 
Cancer of the cervix uteri is the most common female cancer in 
developing countries. Worldwide about 500 000 women acquire the 
disease annually and about 75% are from developing countries (1). About 
300,000 women die of the disease annually.  
In Africa, cervical cancer incidence is highest in Eastern Africa followed 
by southern part of the continent. The incidence is less in Northern Africa 
and is least in some more developed countries in the continent (2). 
Cancer of cervix is the second most common cancer of woman 
worldwide after cancer of the breast and the commonest in developing 
countries (9).  
The worldwide incidence of cancer cervix in terms of 100,000 women-
years is 16.1 and the death rate is 8. In the Asian subcontinent, the 
incidence is even more and reported to be 26.5 and the death rate is 
almost doubled to 15(2). Inspite of being such a major health problem in 
developing countries, cervical cancer screening programs are small scale 
or nonexistent. Consequently, there are few opportunities to diagnose 
precancerous lesions and most patients present with invasive disease at an 
advanced stage. Over the years, pap smear based cytology screening has 
been practiced.  
In less-developed countries, provision for pap smear is available, but 
usually only in urban areas or in the private health sector that serves a 
small proportion of the female population. Pap smear requires technical 
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capabilities, communication, follow up and training-beyond the capacity 
of healthcare infrastructure in many of the developing countries. Further 
more, such screening may not be available at the grass-root level of the 
community. Thus, other methods of cervical cancer screening have been 
investigated. One such method is unmagnified naked eye visual 
examination of uterine cervix after application of 5% acetic acid, termed 
“VIA”. 
In Sudan cancer of the cervix is the second most killer cancer, next to 
breast cancer. Although much has not been done on cervical carcinoma, 
WHO special report on this particular cancer in Sudan (2007), said that it 
was the second by about 18% (3). There is no report about this from 
South Sudan. The pie chart (Fig. 1) below depicts the situation in Sudan 
in 2001 report (87) 
 
 
 
 
 
 
  
 
 
Fig. 1.1. 
Distribution of cervical cancer among different age groups of the study sample
(2001)
1% 10%
26%
18%
41%
4%
20 - 29
30 - 39
40 - 49
50 - 59
60 -
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Until recently the etiology of cancer of the cervix has not been clear. 
Many suggestions were made to link cancer of the cervix with certain 
viral infections. 
 In the seventies and early eighties Cytomegalovirus and Herpes Simplex 
II were implicated as their proteins were found in a large number of 
invasive cervical cancer lesions (5). 
Until recently the Human Papilloma Virus (HPV) had not been linked 
with the pathogenesis of cervical cancer. Human Papilloma Virus has 
been known since antiquity to be associated with warty growths of the 
hands, vulva and vagina and other parts of the skin (6) but the link with 
cancer of the cervix has now been elucidated. 
HPV is now considered a sexually transmitted disease with particular 
types being highly oncogenic. The WHO’s International Agency for 
Research on Cancer (IARC) has classified the HPV into three groups: 
“carcinogenic (HPV types 16 and 18); probably carcinogenic (HPV types 
31 and 33) and possibly carcinogenic (other HPV types except 6 and 11) 
(7). Today over 120 types of  HPV have been described. Other risk 
factors involved  in the genesis of the condition include  sexual 
behaviour, oral contraceptives, Chlamydia infection, low socioeconomic 
status, age, HIV, drugs, just to mention a few. The diagnosis of genital 
HPV infection has been done by indirect means (cytology). Recently 
highly specific HPV DNA tests (e.g. Polymerase Chain Reaction tests 
and the Hybrid II Capture tests) have been developed for the detection of 
HPV in cervical / vaginal preparations. These tests are very sensitive and 
could contribute significantly to the early detection of the virus in the 
genital tract in the very near future. 
Screening for precursor lesions of the cervix have been in use for a long 
time in the industrially advanced countries. The screening test has led to a 
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marked reduction in cervical cancer death rate by about 70% (8). The 
main screening test, the Pap smear, developed by George Papanicolaou in 
1943 has been the gold standard for the detection of pre-malignant and 
indeed early malignant lesions of the cervix.  
In developing countries or low resource countries, the development of the  
naked eye visual inspection of the cervix (VIA) is likely to help reduce 
the high morbidity and mortality associated with cancer of the cervix. The 
VIA has been shown to be sensitive and specific enough to take the role 
of a good screening method. It has also been shown to be easy to teach to 
nurses and midwives to perform the test and to go one step ahead to treat 
premalignant changes in the cervix by cryotherapy.  
With the advances in technology vaccines have been developed against  
HPV with the hope of achieving primary prevention of the disease.  
 
1.1. CERVICAL NEOPLASIAS 
The cervix is the lower part of the uterus (womb). The upper part, or body 
of  the uterus, is where a fetus grows. The cervix connects the body of the  
uterus to the vagina (birth canal). The part of the cervix closest to the 
body of the uterus is called the endocervix. The part next to the vagina is 
the ectocervix. Most cervical cancers start where these two parts meet. 
Cancer of the cervix (also known as cervical cancer) begins in the lining 
of the cervix. Cervical cancers do not form suddenly. Normal cervical 
cells gradually develop precancerous changes that turn into cancer. 
Doctors use several terms to describe these precancerous changes, 
including cervical intraepithelial neoplasia (CIN), squamous 
intraepithelial lesion (SIL), and dysplasia. 
Some women with precancerous changes of the cervix will develop 
cancer.  
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This process usually takes several years but sometimes can happen in less 
than a year. For most women, precancerous cells will remain unchanged 
and go away without any treatment. But if these precancers are treated, 
almost all true cancers can be prevented. Precancerous changes can be 
separated into different categories based on how the cells of the cervix 
look under a microscope. There are several systems for naming and 
describing these categories of potentially cancerous or precancerous 
changes. The most widely used system is discussed below. 
There are 2 main types of cervical cancers: squamous cell carcinoma and  
adenocarcinoma. Other variants such as basaloid squamous cell 
carcinoma, neuroendocrine carcinoma, adenosquamous carcinomas or  
mixed carcinomas. 
Cervical cancers and cervical precancers are classified by how they look  
under a microscope. About 80% to 90% of cervical cancers are squamous  
cell carcinomas, which are composed of cells that resemble the flat, thin  
cells called squamous cells that cover the surface of the endocervix.  
Squamous cell carcinomas most often begin where the ectocervix joins 
the endocervix. The remaining 10% to 20% of cervical cancers are 
adenocarcinomas. Adenocarcinomas are becoming more common in 
women born in the last 20 to 30 years. Cervical adenocarcinoma develops 
from the mucus-producing  gland cells of the endocervix. Less 
commonly, cervical cancers have features of both squamous cell 
carcinomas and adenocarcinomas. These are called adenosquamous 
carcinomas or mixed carcinomas. 
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Fig. 1.2. Female Genital Tract. 
 
1.2. Epidemiology  and  Incidence 
Cancer of cervix is the second most common cancer of woman 
worldwide after cancer of the breast and the commonest in developing 
countries (9). The worldwide incidence of cancer cervix in terms of 
100,000 women-years is 16.1 and the death rate is 8. In the Asian 
subcontinent, the incidence is even more and reported to be 26.5 and the 
death rate doubled to 15 (2). 
In the Sudan, it is considered the second most common  killer disease of 
women next to breast cancer. Although much has not been done on 
cervical carcinoma WHO special report on this particular cancer in Sudan 
(2007), said that it was the second by about 18% (3). There is no report 
about this from South Sudan. 
In Africa, cervical cancer incidence is highest in Eastern Africa followed 
by southern part of the continent. The incidence is low in Northern Africa 
and is least in some more developed countries in the continent (2). 
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In the United States, it is only the 8th most common cancer of women. In 
1998, about 12,800 women were diagnosed in the USA and about 4,800 
died (10). Among gynecological cancers it ranks behind endometrial 
cancer and ovarian cancer. The incidence and mortality in the USA are 
about half those for the rest of the world, which is due in part to the 
success of screening with the Pap smear (10). 
In Great Britain, the incidence is 9.1/100,000 per year (2005), similar to 
the rest of Northern Europe, and mortality is 3.1/100,000 per year (2006) 
(Cancer Research UK Cervical cancer statistics for the UK) (11). With a 
42% reduction from 1988-1997 the NHS implemented screening 
programme has been highly successful, screening the highest risk age 
group (25-49 years) every 3 years, and those ages 50-64 every 5 years. 
Worldwide it is estimated that there are 473,000 cases of cervical cancer, 
and 253,500 deaths per year (12). 
1.3. History 
In the year 400 BCE,  Hippocrates discovered that cervical cancer 
incurable. This was followed by several breakthrough in the twentieth 
century, in which Hans Hinselmann invented a Colposcope. Few years 
later, George Papanicolaou developed Pap smear technique in 1928. In 
1941, both Papanicolaou and Trout performed Pap screening. This was 
followed by the discovery of spatula for scraping the cervical material in 
1946 by Ayer. In 1976, Zur Hausen and Gisam found HPV DNA in 
cervical cancer and warts. In 1988, Bethesda System for Pap results were 
developed which became the basis of classification for cervical cancer.  
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1.4. Epidemiologists working in the early 20th century noted that: 
1. Cervical cancer was common in female sex workers.  
2. It was rare in nuns, except for those who had been sexually active 
before entering the convent. (Rigoni in 1841)  
3. It was more common in the second wives of men whose first wives 
had died from cervical cancer.  
4. It was rare in Jewish women (13). 
5. In 1935, Syverton and Berry discovered a relationship between 
RPV (Rabbit Papillomavirus) and skin cancer in   rabbits. (HPV is 
species specific and therefore cannot be transmitted to rabbits)  
This led to the deduction that cervical cancer could be caused by a 
sexually transmitted agent. Initial research in the 1950s and 1960s put the 
blame on smegma (e.g. Heins et al 1958) (14), but it wasn't until the 
1970s that Human Papilloma virus (HPV) was identified. A description 
by electron microscopy was given earlier in 1949 and HPV-DNA was 
identified in 1963. It has since been demonstrated that HPV is implicated 
in virtually all cervical cancers. Specific viral subtypes implicated are 
HPV 16, 18, 31, 45 and others (15). 
1.5.  Aetiology  And  Risk  Factors 
A number of papers reviewed the etiology of cervical carcinoma. In the 
1960s and 1970s and early eighties the cause of cervical carcinoma was 
attributed to the Cytomegalovirus and later the Herpes Simplex Type II 
infections (16)  as viral antibodies were found in cervical cancer patients.  
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After many years of research it has now become evident, beyond all 
reasonable doubt, that the cancer is closely related to certain highly 
oncogenic strains of  the HPV, notably types 16 and 18  (1, 17). A press 
release in 1996 by the WHO (1) , summarizing the conclusions of an 
informed Technical Consultation involving, 55 experts from 17 countries, 
declared HPV as a major cause of the cancer of the cervix. 
1.6. The etiology of cervical carcinoma is currently established as: 
I-Age:  
The average age of women newly diagnosed with cervical cancer is 
between 50 and 55years. This cancer rarely occurs in girls younger than 
15. It begins to appear in women in their twenties. Cervical cancer is 
different from most cancers that tend to occur more often as people get 
older. Although cervical cancer does affect young women, many older 
women do not realize that the risk of developing cervical cancer is still 
present as they age, and that it is important for them to continue having 
regular Pap tests at least until age 70, and possibly longer.  
 
II- Sexual Behaviour : 
 Epidemiological studies conducted during the past 30 years have  
consistently indicated that cervical cancer risk is strongly influenced by  
measures of sexual activity: number of sexual partners, age at first sexual  
intercourse and sexual behaviour of the woman's male partners (18).  
Circumstantial evidence for sexual transmission of an infectious agent 
comes  from studies showing that wives of patients with penile cancer are 
at an increased risk of cervical cancer later in life. Such findings are 
further supported by results from correlation studies, in which strong 
associations  were found between cervical and penile cancer mortality and 
incidence. 
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III- Human Papilloma Virus: 
Much research has been done to characterize Human Papilloma Virus. 
In 1995 the WHO (6)   published in its monograph the Summary of Data 
Reported and Evaluation of the Human Papilloma Virus. In this 
monograph much of the information on HPV has been summarized. HPV, 
a Papovavirus, is a small double-stranded DNA virus with a diameter of 
55 nm. It is encased in a protein capsid with the viral genome existing in 
a circular or epitomal configuration. The viral genome can be divided into 
3 regions: the Upstream Regulatory Region (URR), the Early Region (E) 
and the Late Region (L). The URR is involved in viral replication and the 
control of transcription in some sequences in the Early region. The Early 
Region encodes for proteins that are responsible for viral replication 
which occurs early in the viral life cycle. The late region encodes for viral 
structural proteins necessary for capsid production late in the viral life 
cycle. The Early Region is responsible for maintaining high numbers of  
HPV and the oncogenic types also encode for proteins that promote the 
transformation of the host cell to cancer (immortalization). There are 
some areas in the Early Region that can encode for proteins and are 
designated as E1, E2, E3, E4, E5, E6 and E7. The E6 and E7 regions are 
responsible for the oncogenic properties of the HPV.  
Thomas Cox et al (19) indicate that nearly 120 types of HPV have been 
described with about 20-30% unclassified. The types are numbered 
according to their discovery and a new type is identified if it has at least 
10% of the gene sequence at E6, E7 and L1 different from any previously 
known type. Types 16, 18, 31, 35, 45, 51, 52 and 56 are considered high 
risk types because of their association with lower genital tract cancers and 
pre-cancers. 
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III.1: Infection Transmission 
It is well established that HPV is transmitted sexually and may persist in 
the genital tract for a very long time with resultant cervical changes. 
Genital-to-genital transmission is easy as micro-trauma at the fourchette, 
labia minora or vagina may enhance the entry of the viruses into the host 
cells. The viruses may take up to 3 months after exposure to show any 
clinical lesion (1, 19) and may take up to 20 years to show carcinomatous 
change. Some of the infections may be sub-clinical without any visible 
expression. As the virus invades the genital cell HPV loses its protein 
capsule but to be infective the capsule is required. The HPV DNA 
therefore exists in the host cell without its shell. Infective HPV may be 
found only in the upper layers of the epithelium where infective genomes 
of HPV are released as dying koilocytes. The 2 late regions of the HPV 
are responsible for proteins involved in the construction of the capsid of 
the infective HPV genome. The infection is usually found at the basal cell 
layer and it does not go through  the basement membrane of the 
epithelium. The infection of the female  genital tract may take 2 main 
courses – transient infection and persistent infection. Up to 65% of 
infected individuals may show disease expression but most of the 
infections quickly resolve due to a complex interplay of host, viral and 
environmental factors with resultant increased dominance over the  viral 
intruder (6,19). When the virus escapes the host's immune reaction the  
infection becomes persistent. Persistence of the viral genome in the host's 
cells may ultimately result in the cervical changes leading to carcinoma   
(6, 19).  
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III.2: Cervical Changes 
The host cell genes p53 and Rb (the retinoblastoma gene) are responsible 
for repairing damages (mistakes, or mutations) during cell replication. If 
the damage is irreparable the cell is destroyed by a process called 
apoptosis. In persistent HPV infection the anti-oncogenic activity of p53 
and Rb is blocked by the production of proteins by E6 and E7 from the 
HPV resulting in un-inhibited host cellular growth and lack of repair of 
damaged cells. Abnormal cell proliferation then results with the 
integration of the viral DNA into the host cellular DNA with resultant 
immortalization of the host cell which then becomes capable of invasion  
( 20 ). Some of the wildly growing cells may develop irreparable, 
permanent changes in the genetic structure (mutation). This eventually 
results in the production of cancerous cells.  
As HPV occupy the host cells various cellular changes occur in the 
epithelial squamous cells detectable by cytology. The first to occur is the 
koilocytic atypia in which the host cellular nucleus is displaced to the side 
with a 'hollow' appearance of the cytoplasm (perinuclear cavitation). (21) 
The squamous cells, as the disease advances, then begin to show signs of 
change in size and shape with sometimes nuclear changes. The cellular 
atypia resulting is termed Atypical Squamous Cells of Undetermined 
Significance (ASCUS). The equivalent in the cervical glandular cells is 
Atypical Glandular Cells of Undetermined Significance (AGUS). About 
60% of such cases may regress spontaneously; 20-35% would persist 
unchanged and the remaining 10% are likely to develop High Grade 
Intra-epithelial Lesion (HGIL) with increased cellular changes, increased 
nuclear/cytoplasmic ratio and mitotic elements. As the whole epithelium 
is replaced with mutant cells cervical intra-epithelial neoplasia (CIN) III 
or carcinoma in situ develops.  
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Tongues of growing squamous cells first break through the basement 
membrane (micro-invasion) and as more tongues grow and coalesce frank 
invasion may occur. Detection of CIN III peaks between 25 – 29 years 
about 4 to 7 years after the peak incidence of CIN I. In Caucasian women 
it takes approximately 15 years after the peak incidence of CIN III to 
develop invasive cancer which may therefore be seen between the ages of 
40 and 45 years (2). 
IV- Smoking: 
 Smoking exposes the body to many cancer-causing chemicals that affect  
more than the lungs. These harmful substances are absorbed by the lungs  
and carried in the bloodstream throughout the body. Tobacco by-products  
have been found in the cervical mucus of women who smoke. 
Researchers believe that these substances damage the DNA of cells in the 
cervix and may contribute to the development of cervical cancer. Women 
who smoke are about twice as likely as nonsmokers to get cervical 
cancer. 
 
V- Human immunodeficiency virus (HIV) infection: 
HIV is the virus that causes the acquired immunodeficiency syndrome  
(AIDS). Because this virus damages the body's immune system, it makes  
women more susceptible to HPV infections, which may increase the risk 
of  cervical cancer. Scientists believe that the immune system is important 
in destroying cancer cells ( 22 ) and slowing their growth and spread. In 
women infected with HIV, a cervical precancer might develop into an 
invasive cancer faster than it normally would. 
VI- Chlamydia infection: 
Chlamydia is a relatively common kind of bacteria that can infect the 
female reproductive system. It is spread by sexual contact. Although  
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infection may cause symptoms, many women do not know they are 
infected  unless samples taken at the time of their Pap test are analyzed 
for this type of  bacteria. Some recent studies suggest that women whose 
blood test results indicate past or current Chlamydia infection are at 
greater risk for cervical  cancer than are women with a negative blood 
test. Although further studies are needed to confirm this finding, there is 
already good reason to avoid this infection and to have it treated with 
antibiotics promptly after diagnosis. Long-term Chlamydia infection is 
well known as a cause of  pelvic inflammation that can lead to infertility. 
 
VII- Diet:  
Women with poor diets may be at increased risk for cervical cancer. Diets  
low in fruits and vegetables are associated with an increased risk of 
cervical cancer and several other cancers. Poor nutrition also increases 
risk, perhaps by depressing the immune system, so a woman is less able 
to fight HPV and cancers. 
 
VIII- Oral contraceptives : 
 No definite evidence exists linking the use of oral contraceptives ( birth 
control pills) with cervical cancer. There is some statistical evidence that  
long-term oral contraceptive (OC) use may slightly increase the risk of  
cancer of the cervix. Some research suggests a relationship between using  
OCs for 5 or more years and an increase in the risk of cervical cancer.  
Research is underway to resolve this issue. In the meantime, the 
American  Cancer Society believes that a woman and her doctor should 
discuss whether the benefits of using OCs outweigh this very slight 
potential risk. A woman with multiple sexual partners should use 
condoms to lower her risk of  sexually transmitted diseases no matter 
what form of contraception she uses. 
15 
 
IX- Low socioeconomic status: 
 Low socioeconomic status is also a risk factor for cervical cancer. Many  
women with low incomes do not have ready access to adequate health 
care  services, including Pap tests and treatment of precancerous cervical 
disease. Such women may also be undernourished, which may play a role 
in increasing their risk. 
 
X- Diethylstilbestrol (DES):  
DES is a hormonal drug that was prescribed between 1940 and 1971 for  
some women thought to be at increased risk for miscarriages. Of every 
1,000 women whose mother took DES when pregnant with them, about 1 
develops clear-cell adenocarcinoma of the vagina or cervix. Stated 
another way, about 99.9% of "DES daughters" do not develop these 
cancers.  Clear cell adenocarcinomas are more common in the vagina 
than the cervix. The risk appears to be greatest in those whose mothers 
took the drug during their first 16 weeks of pregnancy. The  average age 
at diagnosis of DES-related clear-cell adenocarcinoma is 19 years. Most 
DES daughters are now between 30 and 60, so the number of new cases 
of DES-related cervical and  vaginal clear-cell adenocarcinoma has been 
decreasing during the past 2 decades. However, this type of cancer has 
recently been found in a woman in her early 40s, and doctors still do not 
know exactly how long women remain at risk for DES-related cancers.    
( 22 ) Although DES daughters have an increased risk of developing clear 
cell carcinomas, about 40% of women with this cancer have not been 
exposed to DES or related medications. Some of these patients’ mothers 
might have taken DES but did not recall the name of the drug. It is 
certain, however, that women don’t have to be exposed to DES for clear 
cell carcinoma to develop since some cases of the disease were diagnosed 
before DES was invented. Some studies suggest that DES daughters are 
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also at somewhat increased risk of developing squamous cell cancer of 
the cervix and precancerous changes of cervical squamous cells. 
 
XI- Family history of cervical cancer: 
 Recent studies suggest that women whose mother or sisters have had  
cervical cancer are more likely to develop the disease, themselves. Some  
researchers suspect this familial tendency is due to an inherited condition  
that makes some women less able  to fight off HPV infection than others. 
XII- Drugs :  The chronic use of corticosteroids such as for unrelenting 
asthmatic attacks and lupus may also play a role in cervical cancer 
formation. 
XIII- Multiparity : This is attributed to more trauma and irritation. 
However, some studies also reported it attribution to hormonal changes. 
XIV- Genetic Factor : There is great  and possible genetic association 
with HLA B7. 
1.7. Pathogenesis and pathology of cervical neoplasia 
1.7.1. COFACTORS AND CERVICAL NEOPLASIA 
Epidemiological studies have thrown up a range of putative cofactors 
involved in progression: Immunosuppression , sex steroid hormones 
(based on associations of cervical cancers with high parity and long term 
use of the oral contraceptive pill), and  smoking. (23,24,25 )  
Furthermore, most of these cofactors appear to influence progression to 
CIN 3 (from latent HPV infection or low grade CIN), rather than CIN 3 
to cancer. The effects of smoking have been well studied and there is a 
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consistent epidemiological association (odds ratio of about 2) between 
cigarette  smoking and cervical cancer. The carcinogenic constituents of 
tobacco smoke are strong candidates for co-carcinogenic factors with 
HPVs in cervical carcinogenesis. Cigarette smokers with mildly abnormal 
cytology are more likely to have larger and more severe histological 
lesions .The constituents of tobacco smoke (such as nitrosamines) can be 
demonstrated in cervical mucus, and increased smoking related DNA 
adducts have been shown in normal epithelium  next to cervical 
intraepithelial and invasive neoplasia, indicating a direct effect on 
cervical epithelium at the DNA level. (26,27,28) Differential cervical 
expression of cytochrome P450 enzymes, which activate carcinogenic 
nitrosamines, and glutathione S transferase, which denatures them, may 
play a role in determining individual susceptibility to tobacco related 
carcinogens ( 29 ). 
1.7.2. ALTERATIONS IN CELLULAR ADHESION  MOLECULES 
Integrins are transmembrane glycoproteins important in interactions 
between epithelial cells and basement membranes. Integrin expression is 
confined to the  basal layer of normal squamous epithelium. However, the 
patterns of integrin expression in neoplastic cervical epithelium differ 
from this, with dysplastic cells expressing integrins throughout the full 
thickness of the epithelium in CIN 3 (30). Epithelial cadherin (E 
cadherin) is a cell-cell adhesion molecule that connects epithelial cells via 
homotypic, calcium dependent interactions .In normal cervix, E cadherin 
is expressed on the cell membrane of basal and parabasal cells. 
Cytoplasmic reactivity is present in occasional basal cells only.  
In CIN, there is increased cytoplasmic reactivity, which is strongly 
correlated with the grade of the CIN lesion. In squamous carcinomas, 
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reduced membranous and increased cytoplasmic reactivity is seen with 
worsening differentiation (31). 
1.7.3. CERVICAL INTRAEPITHELIAL NEOPLASIA 
The normal cervix is covered on its outer surface by a non-keratinizing, 
stratified squamous epithelium, which is continuous below with the 
squamous epithelium lining the vagina, and above abuts onto the mucus 
secreting columnar epithelium lining the endocervical canal and its 
associated crypts. The junction between the two epithelia normally 
coincides with the external cervical os but this is not a constant relation. 
At puberty, in pregnancy (particularly the first one), and in some steroid 
contraceptive users, changes in the size and shape of the cervix result in 
the squamocolumnar junction being carried out on to the anatomical 
ectocervix. This exposes the tissues previously found in the lower 
endocervical canal to the vagina. This is a physiological process and the 
exposed tissue forms the "cervical ectopy". It is from the epithelium that 
covers the ectopy that most CINs and invasive carcinomas develop. 
Under physiological conditions, the columnar epithelium of the ectopy 
undergoes metaplasia to a stratified squamous epithelium, and it is during 
this metaplastic process that the epithelium seems to be particularly  
vulnerable to oncogenic viruses, and perhaps to other factors resulting in 
the  development of an intraepithelial neoplasm rather than a normal 
epithelium.  
The intraepithelial neoplasm may be of squamous or columnar cell type. 
CIN is recognized by disturbances of cellular maturation and 
stratification,  and by the presence of cytological atypia. It is customarily 
graded according  to the degree of cytoplasmic maturation (32) but, by 
definition, nuclear atypia  must be present at all levels of the epithelium. 
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It affects the surface  epithelium and extends down into the underlying 
crypts. In younger women,  CIN lies on the ectocervix where the ectopy 
has formed, but in older women  the tissues that form an ectopy are 
withdrawn into the endocervical canal,  therefore, CIN in older women 
tends to lie within the endocervical canal  where it may be more difficult 
to sample. CIN initially forms a single area and thus, if section margins of 
tissue removed for its treatment are free from disease, it is likely that the 
whole of the lesion has been removed (32). 
1.7.4. Histopathological diagnosis of cervical intraepithelial neoplasia 
In Europe, CIN is usually divided into three grades, although other 
schemes  are used (32). The lesions range from a well differentiated 
intraepithelial  neoplasm  (CIN 1) to a poorly differentiated intraepithelial 
neoplasm (CIN 3). CIN 2 occupies an intermediate position.  
The differentiation of CIN is rarely uniform throughout the affected area, 
the  most poorly differentiated component tending to lie adjacent to the 
columnar epithelium of the endocervical canal. For a diagnosis of CIN, 
nuclear abnormalities such as enlargement, pleomorphism, and 
hyperchromasia must  be present at all levels in the epithelium, including 
the basal layer. Hyperchromasia is not a prerequisite, and in some forms 
of CIN the nuclei do not stain darkly. The degree of nuclear atypia tends 
to be greater in CIN 3 than in CIN 1. Normal mitoses vary in number and 
do not affect the diagnosis, while atypical mitoses may be present in all 
grades of CIN.  
In CIN 1, cytoplasmic maturation occurs in the superficial two thirds of 
the  epithelium. In CIN 2 it starts in the middle third of the epithelium, 
and in  CIN 3, cytoplasmic maturation, which is minimal or even absent, 
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occurs only in the most superficial third of the epithelium. Changes 
usually attributed to the presence of HPV infection, such as koilocytosis 
and epithelial multinucleation, are often present and are most conspicuous 
in  CIN 1 and 2, and minimal or absent in CIN 3. This may be a reflection 
of viral integration in the high grade lesions. Most histopathologists in the 
UK have not accepted the two tier Bethesda  system for  Arends, 
Buckley, and  Wells on  cervical intraepithelial abnormalities, (33) but 
have chosen to retain the present grading system, together with a recently 
introduced category of epithelial abnormality to encompass lesions in 
which a diagnosis of CIN cannot be made with certainty: basal 
abnormality of uncertain significance. (32) This category may be 
particularly useful in combating the problem of over diagnosis of CIN 1, 
still thought to occur to a considerable extent, because pathologists fail to 
appreciate that, even in a CIN 1 lesion, the nuclei are abnormal 
throughout the full thickness of the epithelium and not just in the lower 
third above which there is cytoplasmic maturation. However, it is 
possible to distinguish between CIN 1 and HPV infection alone by virtue 
of the presence of koilocytosis without nuclear atypia. 
CIN1 (Grade I), the least risky type, represents only mild dysplasia, or 
abnormal cell growth and corresponds to a low grade squamous 
intraepithelial lesion (LGSIL). It is confined to the basal 1/3 of the 
epithelium. This corresponds to infection with HPV, and typically will be 
cleared by immune response in a year or so, though it can take several 
years to clear.  
CIN2/3 correspond to high grade squamous intraepithelial lesions 
(HSIL).   
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Sometimes this is further divided: CIN2 (Grade II): Moderate dysplasia 
confined to the basal 2/3 of the epithelium CIN3 (Grade III). 
 Severe dysplasia that spans more than 2/3 of the epithelium, and may 
involve the full thickness. This lesion may sometimes also be referred to 
as cervical carcinoma in situ.  
1.7.5. Natural history of cervical intraepithelial neoplasia 
Review of the world literature  on the natural history of CIN indicates 
that the approximate likelihood of regression of CIN 1 is 60%, 
persistence 30%, progression to CIN 3 10%, and progression to invasion 
1%. The corresponding approximations for CIN 2 are 40%, 40%,20%, 
and 5%, respectively. The likelihood of CIN 3 regressing is 33% and 
progressing to invasion greater that 12%. Thus, even the higher degrees 
of atypia may regress in a significant proportion of cases, and although 
the probability of an atypical epithelium becoming invasive increases 
with the severity of the atypia, this does not occur in every case. As 50-
60% of the lesions diagnosed as CIN 1 will regress spontaneously, if 
clinicians intervene at such an early phase of the process it may result in 
the unnecessary treatment of women who are at little or no risk of 
developing carcinoma. A balance has to be struck, however, between 
unnecessary treatment and a failure to eradicate a lesion that has the 
potential to progress to invasive carcinoma. In general, persistence of 
CIN 1 is regarded as an indication for eradication. It is also recognised 
that higher grade lesions of CIN 2 and 3 are more likely to progress to 
invasive carcinoma and are usually treated without undue delay. 
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1.7.6. Invasive Potential of CIN 3 
No one doubts the malignant potential of high grade CIN since the 
debacle  at the National Women's Hospital in Auckland, New Zealand in 
the 1970s, in which many women with persistent abnormal cytology 
following biopsy of" carcinoma in situ" (as it was called at that time) 
were treated  conservatively. Twenty nine % developed invasive cancer 
(compared to 1.5% of a control group), and eight died (34).  The main 
histological features identified in CIN 3 associated with microinvasive 
carcinoma or predictive of subsequent microinvasion are extensive 
involvement of surface epithelium and deep endocervical crypts by 
expansile CIN 3, luminal necrosis, and intraepithelial squamous 
maturation (35).  Other features more commonly present in CIN 3 
associated with microinvasive carcinoma include frequent mitosis and 
apoptosis, pericryptal concentric fibroplasias, pericryptal inflammatory 
infiltrates, keratin pearls pronounced cellular pleomorphism, certain 
nuclear changes (distinct nucleoli and chromatin clearing), and the 
emergence of streams of darkly staining spindle cells orientated at right 
angles to the basement membrane (35).  
In a prospective study (40), 83% of cases illustrating the major 
microinvasive carcinoma associated features revealed evidence of 
microinvasive carcinoma or frank invasion either on serial sections of the 
original biopsy or on subsequent biopsy. None of the 64 cases of CIN 3 
that lacked these features showed evidence of invasion on serial sections 
or on follow up over 18 months. These sections were performed to 
exclude the presence of microinvasion, and closer clinical follow up of 
these patients was appropriate (40). 
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1.7.7. INVASIVE CARCINOMA OF THE CERVIX 
Most invasive carcinomas of the cervix develop from an intraepithelial 
neoplasm that has formed in the tissues of the cervical ectopy (32, 36).  
They tend to lie, therefore, on the ectocervix in younger women and in 
the endocervical canal in older woman. The tumours may have an 
exophytic or endophytic pattern of growth. Those on the ectocervix being 
more commonly exophytic and those in the endocervical canal more 
commonly endophytic. This has clinical importance in that exophytic 
tumours on the ectocervix are less likely to have extended into the 
adjacent tissues and organs than endophytic tumours of similar size, and 
are less likely to have metastasized. Cervical carcinomas spread locally 
into the cervical stroma, the paracervical and parametrial tissues, the body 
of the uterus, the vagina, and late in the course of the disease, to the 
bladder and rectum (32). Lymphatic permeation in the cervical stroma 
may occur even when the tumour is of low volume, therefore, metastases 
may be found in the pelvic lymph nodes even when the tumour is small. 
It is not possible, therefore, to equate "small" with "early" carcinoma    
(32 ). 
1.7.8. MICROINVASIVE SQUAMOUS CARCINOMA OF THE 
CERVIX 
It is customary to stage invasive carcinomas of the cervix according to the 
criteria laid down by FIGO ( 37,38,39 ). The FIGO guidelines do not use 
the term microinvasive carcinoma, but stage 1A, which encompasses 
lesions that can be diagnosed only on microscopy, and are usually 
regarded as being synonymous with microinvasive carcinoma. When 
invasive disease is identified unexpectedly in women who have been 
regularly screened, the carcinomas often come into this category. Such a 
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finding should not be regarded as a failure of the screening process 
because such neoplasms carry only a low risk of metastatic disease and 
can, therefore, usually be treated relatively conservatively. FIGO has 
recently modified its classification of microinvasive carcinoma by 
subdividing stage 1A. Stage 1 (carcinoma strictly confined to the cervix) 
is divided into stage IA (invasive cancer only identified histologically) 
and stage1B (gross lesions even those with only superficial invasion). 
Stage 1A is further divided into stage lAl (invasion of stroma up to 3 mm 
in depth and no wider than 7 mm) and stage 1A2 (invasion of stroma of 
3-5 mm in depth and no wider than 7 mm). There have only been three 
cases of nodal metastases in 1543 patients in the literature whose 
microinvasive carcinomas invaded the stroma to 1 mm or less (termed 
early stromal invasion). Therefore it appears that early stromal invasion 
behaves in the same manner as high grade CIN and may be treated by 
conisation alone provided the cone has been adequately sectioned, the 
margins are free from tumour, and the curettings do not contain abnormal 
epithelium. For microinvasive carcinomas invading between 1 and 3 mm, 
nodal involvement was found in only five of 809(0.6%) patients who had 
pelvic lymph node dissection, and the vast majority of these cases can 
also be safely treated by conisation alone. For tumours penetrating         
3-5 mm (FIGO stage1A2), there appears to be a higher risk of recurrence 
and nodal metastasis; nodal involvement has been reported in 14 of 214 
patients (6.5%). (40). 
The introduction of the revised staging system has recently been 
criticized. (41)  The term early stromal invasion (up to 1 mm invasion) is 
missing in the new version of the staging system and has been replaced 
by "microinvasion changes" with a depth of invasion up to3 mm. This 
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group will inevitably include a large number of cases of early stromal 
invasion (< 1 mm). 
Burghardt et al ( 41) reviewed cases in the literature with invasion of 1-
3 mm (cases with early stromal invasion (< 1 mm) were excluded) and 
found that 1.4% of patients died of disease. (41)That is six times more 
than the death rate of patients with early stromal invasion (< 1 mm) and 
not significantly different from the proportion of patients (1.7%) dying of 
cancer whose neoplasms extend to a depth of between 3 and 5 mm at 
diagnosis. These authors feel, therefore, that it is inappropriate to dilute 
the stage lAl group with a large number of cases in an extremely low risk 
category (those showing early stromal invasion of < 1 mm), which makes 
treatment results highly favorable. They consider that only early stromal 
invasion (< 1 mm) merits recognition as a separate category. 
There is no convincing evidence in the literature that capillary-like space 
involvement is associated with lymph node metastases or an increased 
incidence of recurrence. Therefore, permeation of endothelial lined 
spaces is ignored for the purposes of staging. The term microinvasive 
carcinoma can be applied to squamous carcinomas, 
adenosquamouscarcinomas, and adenocarcinomas (see below). It cannot, 
however, be used for small cell (neuroendocrine) tumours to which the 
term microinvasive carcinoma should not be applied even when the 
tumour is small enough to be stage IA. Stromal invasion from both a 
squamous and columnar cell intraepithelial neoplasm is recognized by 
loosening of the stroma at the point of invasion, and the presence of a 
variable stromal round cell infiltrate. In the epithelium, at the point of 
invasion, there is often a subtle change in the pattern of tumour cell 
differentiation with increased eosinophilia of the cytoplasm and a change 
in the degree of nuclear atypia. It is important for clinical  management 
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that the depth of invasion is measured accurately for microinvasive 
carcinomas, taken from the base of the epithelium (either surface or 
glandular) from which it originates (41). 
1.7.9. WHAT IS AN EARLY CARCINOMA OF THE CERVIX? 
There is some agreement that stage 1A carcinomas can be described as 
"early" although this may be a simplistic view of lesions that may be of 
limited invasive capacity rather than early. Tumours that are too large to 
be encompassed by the definition of stage 1A but are still confined to the 
cervix are included in stage 1B. For tumors of stage 1 B and higher, 
radical treatment is required and it would be inappropriate to include such 
lesions in a description of early cervical tumours, although it could be 
argued that the term early carcinoma could include all invasive lesions for 
which surgery is the first line of treatment (42). It has been customary to 
regard stages 1 A,1 B, and 2A carcinomas as early lesions; however, as 
metastatic disease may already be present in women with stages 1A2, 1B, 
and 2A disease it is clearly inappropriate to call these tumours  early. 
Moreover, the pathologist is rarely in a position to identify, with any 
certainty, the woman at risk of having metastatic carcinoma from the 
appearance of the initial cervical biopsy in which the invasion is 
recognized. It is more important to consider not just the size of the lesion 
at the time of diagnosis, which is the result of a balance between tumour 
cell gain and loss, but also to consider the biological aggressiveness of 
the invasive lesion and, to this end, studies of oncogene activation and 
over expression, and disturbances of tumour suppressor genes have been 
done (42).  It is apparent from these studies that small volume tumors 
may behave in quite different ways and many are, in apparent 
contradiction to their small size, actually advanced carcinomas (43). 
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1.7.10. CERVICAL GLANDULAR INTRAEPITHELIALNEOPLASIA 
The term cervical glandular intraepithelial neoplasia (CGIN) is now used 
to encompass adenocarcinoma in situ and glandular atypia in the 
endocervix. CGIN is much less common than CIN but, as with CIN, most 
CGIN lesions occur in the region of the cervical ectopy. In contrast to 
CIN, in about 10% of CGIN cases, separate foci may be found higher in 
the endocervical canal (44). Both the surface epithelium and the 
underlying crypts may be affected by the process, and the junction 
between the atypical columnar epithelium and the normal columnar 
epithelium is invariably abrupt. In typical CGIN lesions there are reported  
cases where disturbances of both crypt architecture and columnar cell 
differentiation (17, 42). Crypts become more complex in shape with out 
pouchings and in folding of the lining, and they come to lie closer 
together than usual. The glandular epithelium is stratified, there is a 
reduction in intracytoplasmic mucin, and an increase in 
nucleo:cytoplasmic ratios. The nuclei are hyperchromatic and 
pleomorphism to a variable degree. Nucleoli may be large and multiple. 
Mitoses are frequent and atypical forms may be present. The columnar 
cells may remain  recognizably endocervical, but intestinal metaplasia is 
not uncommon. The criteria for grading CGIN are not fully established or 
agreed, therefore, it is suggested that until the grading system is further 
evaluated, the range of  CGIN lesions be termed either high grade CGIN, 
corresponding to adenocarcinoma in situ, or low grade CGIN for lesser 
degrees of  abnormality (45).  The premalignant potential of high grade 
CGIN (adenocarcinoma in situ) is not in doubt, but the true natural 
history of low grade CGIN remains uncertain. 
CGIN often co-exists with squamous CIN 4 and for this reason may 
sometimes be overlooked. Abnormalities of oncoprotein expression have 
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been demonstrated in CGIN. The association between CGIN and HPVs is 
less clear cut than for squamous lesions, but a high proportion of 
adenocarcinomas are HPV positive using  the sensitive polymerase chain 
reaction technique. ' Some workers have suggested that HPV type 18 is 
implicated more in adenocarcinoma than in squamous lesions (45) 
1.7.11. ADENOCARCINOMA OF THE CERVIX 
Invasive adenocarcinoma is reported to be increasing in incidence, 
particularly in young women, and there have been suggestions of a link 
between cervical adenocarcinoma and the contraceptive pill, particularly 
with prolonged use. The practical assessment of microinvasive 
adenocarcinoma of the cervix is much more difficult than its squamous 
counterpart, because recognition of the point of invasion and therefore its 
measurement is associated with problems of definition. However, recent 
work confirms that lesions with a volume of less than 500 cubic mm have 
a negligible risk of local recurrence and lymph node metastases. It is 
probably not practical on a day to day basis to express invasion in three 
dimensions, and gynecologists tend to be less conservative in their 
treatment of microinvasive adenocarcinomas arising in the endocervix 
than microinvasive squamous cervical carcinomas (44). 
1.8. CLINICAL MANIFESTATIONS 
Many cases are detected by screening. However, symptoms require full 
pelvic examination including use of speculum. 
1.8.1. First symptoms of established cervical carcinoma are: 
• Vaginal discharge; varies greatly in amount and can be intermittent 
or continuous. 
29 
 
• Bleeding; can be spontaneous but may occur after coitus 
(postcoital), micturition or defecation in early stages. Patients may 
ignore this if scanty and ascribe it to normal menstrual dysfunction. 
Occasionally, severe vaginal bleeding may necessitate emergency 
hospital admission.  
• Vaginal discomfort/urinary symptoms  
1.8.2. Later symptoms may include: 
• Painless haematuria  
• Chronic urinary frequency  
• Painless fresh rectal bleeding  
• Altered bowel habit  
• Leg oedema, pain and hydronephrosis leading to renal failure are 
ominous, late signs indicating pelvic wall involvement.  
• With more advanced disease patients develop pelvic discomfort or 
pain that is poorly localized and described as dull or boring in the 
suprapubic or sacral regions. It is similar to menstrual discomfort, 
can be persistent or intermittent and may be confused with 
arthropathy.  
 Symptoms may prompt patient to seek a cervical smear. Smear 
test is useful for detecting pre-cancerous lesions, but not 
carcinoma. If any degree of suspicion of cervical carcinoma then 
examine carefully and consider urgent referral for further 
assessment.  
1.8.3. Signs 
In early-stage cervical cancer, examination can be relatively normal. 
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• There may be white or red patches on the cervix. As the disease 
progresses it can lead to an abnormal appearance of the cervix and 
vagina, due to erosion, ulcer or tumour.  
• Rectal examination may reveal a mass or bleeding due to erosion.  
• Bimanual palpation may reveal pelvic bulkiness/masses due to 
pelvic spread.  
• Leg oedema may develop due to lymphatic or vascular obstruction.  
• Hepatomegaly may develop in the case of liver metastases.  
• Pulmonary metastases are normally only detected if they cause 
pleural effusion or bronchial obstruction.  
1.9. Differential diagnosis  
• Cervicitis  
• Dysfunctional uterine bleeding  
• Cervical erosion (ectropion)  
• Pelvic inflammatory disease  
• Endometrial carcinoma  
• Side-effects of IUCD use  
• Endometrial hyperplasia  
• Fibroids  
• Atrophic vaginitis  
1.10. Investigations  
• Colposcopy - allows examination of the visible cervix, usually 
including the transformation zone  
o Cervix is first cleaned with acetic acid , which highlights the 
abnormal area on the cervix  
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o Cervix can then be inspected, biopsied and treated if 
necessary.  
• Pap smear screening test; detects precancerous cells, cancerous and 
invasive tumor cells on the cervix. 
• Cone biopsy ; for confirmation of the diagnosis of cervical cancer 
and precancerous conditions 
• FBC (for anaemia)  
• Renal function tests, LFTs  
• Chest X-ray (to seek metastases) and IV urogram  
• CT scanning of the pelvis and abdomen - used to stage disease, 
along with relevant biopsies  
• Barium enema or proctoscopy - used to assess rectal 
compression/invasion  
• Cystoscopy - to assess bladder invasion  
• MRI - gives clear picture of primary tumour, local invasion and 
nodal  
1.11. Staging 
Cervical cancer is staged by the International Federation of Gynecology 
and Obstetrics (FIGO) staging system, which is based on clinical 
examination, rather than surgical findings. It allows only the following 
diagnostic tests to be used in determining the stage: palpation, inspection, 
Colposcopy, endocervical curettage, hysteroscopy, Cystoscopy, 
proctoscopy, intravenous urography, and X-ray examination of the lungs 
and skeleton, and cervical conisation. 
The TNM staging system for cervical cancer is analogous to the FIGO 
stage. 
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1.12. FIGO staging  
(Stage)  
 
0 
(Description) 
 
Carcinoma in situ (pre-invasive) 
I Cervical carcinoma confined to uterus (disregard extension to corpus) 
Ia Invasive carcinoma diagnosed only by microscopy (all visible lesions, even superficial ones 
are 1B) 
Ia1 Stromal invasion 3mm depth and 7mm horizontal spread 
Ia2 Stromal invasion >3 to <5mm with 7mm horizontal spread 
Ib Clinical visible lesions confined to the cervix or lesion visible on microscopy >IA2 
Ib1 Clinically visible lesion 4cm in largest dimension 
Ib2 Clinically visible lesion >4cm in largest dimension 
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II Tumour invades beyond uterus but not to pelvic wall or lower third of vagina 
IIa No parametrial invasion 
IIb Parametrial invasion 
III Tumour extends to pelvic wall and/or involves lower third of the vagina and/or causes 
hydronephrosis or kidney cannot function 
IIIa Tumour involves lower third of vagina, no extension to pelvic wall 
IIIb Tumour extends to pelvic wall and/or causes hydronephrosis or kidney to not work 
IV/Iva Tumour invades mucosa of bladder or rectum and/or extends beyond true pelvis 
IVb Distant metastases 
 
1.13.TREATMENT 
Most HPV-induced cervical cell changes are transient, and 90% regress 
spontaneously within 12 to 36 months as the immune system eliminates 
the virus. The primary immune response to HPV infection is a cell-
mediated response induced at local lymph nodes. A humoral immune 
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response also develops, but local levels of HPV-specific immunoglobulin 
G (IgG) and  IgA in tissue do not correlate with clearance of virus . 
Systemic levels of HPV-specific IgA were correlated with virus 
clearance. Systemic levels of HPV-specific IgG were detected more 
frequently in patients with persistent HPV infection. The tendency toward 
regression of HPV infection correlates inversely with the severity of 
cervical disease. Only a small proportion of mild and moderate cervical 
diseases develop into invasive cancer, but the risk of progression from 
severe cervical cellular abnormality to invasive carcinoma is at least 12%. 
Factors such as genetic predisposition, frequency of reinfection, intratypic 
genetic variation within HPV type, coinfection with more than one HPV 
type, hormone levels, and immune response may influence the ability to 
clear an HPV infection. A number of factors such as size, stage, and 
histologic features of the tumor, lymph node involvement, risk factors for 
complications from surgery or radiation, and patient preference determine 
the course of treatment (74, 75).  
In general, noninvasive intraepithelial lesions identified only 
microscopically are treated with superficial ablative procedures such as 
cryotherapy or laser therapy. These are outpatient office procedures, and 
fertility is maintained.  
With cryotherapy, abnormal tissue and the surrounding 5 mm is frozen 
with a supercooled probe. A single freeze is usually not adequate to 
induce necrosis, so the area is allowed to thaw and is frozen again.  
Ablation of tissue with a carbon dioxide laser beam is as effective as 
cryotherapy, and the tissue heals faster with less distortion, but the 
procedure is more expensive. 
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Loop electrosurgical excision procedures are now considered to be the 
preferred treatment for noninvasive squamous lesions. In these 
procedures, an electrically charged wire is used to excise the 
transformation zone and distal endocervical canal. It is less expensive 
than laser therapy and preserves the excised tissue for histological 
examination of margin status.  
Following treatment of noninvasive intraepithelial neoplasia lesions by 
any  technique, there is always a potential risk of leaving dysplastic cells 
behind. Recurrence rates as high as 31% with a mean time to recurrence 
of 11. 9 months have been reported following loop diathermy procedures 
in immunologically normal patients . Patients with positive margins had a 
higher recurrence rate (47%) than did those with clear margins (26%). 
Human immunodeficiency virus-infected women have a significantly 
higher recurrence rate (87%) than do uninfected women (18%), indicating 
the importance of an effective immune system in resolution of HPV-
associated disease. Progression to invasive disease is rare (< 2% in most 
series). However, these data emphasize the importance of follow-up 
surveillance in treated patients. Preliminary evidence suggests that 
detection of HPV DNA using molecular techniques may be able to help 
detect residual lesions following treatment. Detection of high-risk HPV 
DNA at 6 months after treatment was more sensitive than abnormal 
cytology findings in patients with moderate or severe cervical disease 
prior to treatment. The negative predictive value of absence of high-risk 
HPV DNA and normal cytologic test results in these patients was 99% 
(17) The utility of HPV DNA testing for residual disease following 
treatment of lower grades of dysplasia remains to be evaluated.  
Microinvasive cancers less than 3 mm in size are managed conservatively 
by excisional cone biopsy. Early invasive cancers are managed with 
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radical hysterectomy or external-beam high-energy (to 18 MV) 
radiotherapy and implants loaded with 192Ir. The goal of this therapy is to 
destroy malignant cells in the cervix, paracervical tissues, and regional 
lymph nodes. Selected patients also benefit from concurrent 
chemotherapy (75).  
Locally advanced cancers are managed with radiotherapy to the primary 
tumor and potential sites of regional spread. In addition to surgical and 
cytodestructive procedures, several antiviral and immunomodulatory 
agents have been evaluated as treatment for HPV-associated cervical 
lesions. Cidofovir is an acyclic nucleoside phosphonate derivative which 
has broad-spectrum activity against DNA viruses and is in use clinically 
for the treatment of CMV infections. Exposure of human carcinoma cell 
lines containing HPV-16 or HPV-18 and human cervical keratinocytes 
immortalized by HPV-33 to cidofovir resulted in inhibition of cell 
proliferation. The in vitro antiproliferative activity was shown to be 
selective for the rapidly proliferating HPV-infected cells when normal 
primary human cervical keratinocytes were treated similarly. A 1% 
cidofovir gel was used topically without side effects every other day for 1 
month to treat 15 women with severe CIN. Complete or partial response 
was seen in 80% of patients as assessed by histology and detection of 
HPV DNA by PCR.  
Podophyllin, a cytotoxic agent that arrests mitosis in metaphase  (also 
used to treat genital warts), in combination with vidarabine, a DNA 
polymerase inhibitor, suppressed HPV gene expression and cell growth in 
cervical cancer cell lines. The expression of HPV-16 E6 and E7 gene 
products in normal cervical keratinocytes in vitro in the presence of either 
podophyllin or vidarabine sensitized these cells to apoptosis. Combined 
topical therapy with podophyllin and vidarabine ointments in 28 patients 
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with mild to moderate CIN resulted in regression of lesions and 
successful eradication of HPV-16 or HPV-18 DNA in 81% of patients. 
The IFNs and intravaginal 5-fluorouracil have shown variable response in 
clinical and in vitro studies. IFN-  is approved for treatment of genital 
warts (75).  
The effects of IFN- , IFN-ß, and IFN-  in several human carcinoma cell 
lines containing HPV-16 or HPV-18 have been studied . Response was 
seen in some cell lines but not others. In HPV-18 HeLa cells, all IFNs 
suppressed  the levels of HPV E6 and E7 gene transcripts. In HPV-18 C-
411 cells, IFNs had no effect. In HPV-16 CaSki and HPK1A cells, only 
IFN-  was effective. It is likely that, since IFN-responsive elements 
appear to be down-regulated by at least some oncogenic HPV types, the 
utility of IFN therapy in cervical disease will be limited (75).  
1.14.PREVENTION 
Primary approaches to prevent HPV infection include both risk reduction 
and development of HPV vaccines. Use of latex condoms and a 
spermicide may decrease the risk of contracting HPV. Condoms, 
however, are not totally reliable, since HPV may be contracted by contact 
with other parts of the body, such as the labia, scrotum, or anus, that are  
not protected by a condom. HPV vaccines are usually composed of virus-
like particles (VLPs), which are empty virus capsids containing the major 
HPV capsid antigen and possibly the minor capsid antigen but lacking 
viral DNA. The vaccines are produced by expressing the  L1 or L1 and 
L2 ORFs in eukaryotic cells. These proteins then self-assemble into VLPs 
which are highly immunogenic. Because of the high level of  antigenic 
specificity of HPV capsid antigens, there is no cross-protection among 
subtypes, and protection against each subtype requires vaccination with 
VLPs of that subtype. Optimal vaccines would contain a cocktail of VLPs 
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of the most common high-risk HPV subtypes. Preliminary reports 
indicate that animal papillomavirus vaccines have excellent 
immunogenicity and protection against experimental animal 
papillomavirus diseases.  
A double-blind, randomized, placebo-controlled phase I safety and  
immunogenicity trial has been conducted using a subunit vaccine 
composed of VLP formed from the entire L1 major capsid protein of 
HPV-16 strain 114K. The vaccine was prepared by inserting the L1 
capsid gene into a baculovirus vector. The gene was then expressed in 
transfected Sf9 insect cells. An optimal dose of 50 µg of HPV-16 L1 VLP 
vaccine was administered by injection into the deltoid muscle at 0, 1, and 
4 months. The vaccine generated high titers of type-specific neutralizing 
antibodies without adjuvant and was well tolerated. 
1.15. LITERATURE REVIEW 
This literature review is undertaken through electronic search using the 
databases such as PUBMED, MEDLINE, Cochrane library ,,,etc and also 
through   international medical journals in order  to find  the most up to 
date studies on the subject. Recent publications from the WHO and 
collaborative institutions such as PATH were also reviewed. Manual 
searches were also conducted at the WHO, The Sudan National Medical 
Specialization  Board and the  Medical  School libraries in the Sudan. An 
extensive body of knowledge is available on this topic but in the Sudan 
there is hardly any information available with exception of WHO office 
in Khartoum.  
Consequently, the search was limited to recent literature published from 
1990-2008. A few references were sought from earlier years. 
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The concept of paper is review all the studies done across world with 
relevant ideas about application of these diagnostic tools use for 
screening Cervical cancers and its precursors.  
 
Jeronimo J and Colleagues in Lima, ( 46 ) performed a prospective 
study on VIA for cervical cancer screening outside of low-resource 
settings, to evaluate VIA as an alternative or adjunct to the Pap smear. 
They found that more women tested positive by VIA than on the Pap 
smear (6.9% vs. 4.2%; P = 0.0001). VIA is useful for detection of 
precursor lesions of Cervical cancer not only in low-resource settings but 
also in well-equipped health centers and cancer centers. In these non-low-
resource settings, VIA has a positive predictive value comparable to the 
conventional Pap smear, but it is more likely to achieve earlier diagnosis, 
follow-up, and treatment than cytology-based screening. 
In my opinion, this screening tool though simple has not been conducted  
here in Sudan at a wider level. I therefore come forward to work on it so 
as to communicate it to clinicians in the rural Sudan.  
 
Tayyeb R & colleaques, ( 47 ) did a comparative studies between VIA 
and Pap at a hospital in Lahore, India. They found that all subjects were 
screened simultaneously by Pap smear and VIA after application of 3% 
acetic acid.  
Positive cases by both screening methods and grossly abnormal cervix 
even with negative screen were subjected to Colposcopy. In case of 
colposcopic abnormality of atypia or advanced lesions, biopsies were 
taken. Histology of colposcopically directed biopsy was taken as gold 
standard to evaluate the performance of the test.  
The results indicate that VIA is more sensitive and has a higher accuracy 
as compared to Pap smear. It could, therefore, be valuable in detection of  
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precancerous lesions of  cervix. Low cost, easy applicability and 
immediate results make VIA a useful screening test in developing 
countries like Sudan as compared to Pap smear. 
 
 Syrjänen K and colleagues, ( 48 ) also did some study by  
comparing PAP smear cytology, aided visual inspection, screening  
Colposcopy, Cervicography and HPV testing as optional screening tools 
in Latin America. However, the first three screening tools are relevant to 
my study.  
Thomas C Wright and his colleagues, (49 )  worked on Visualization 
Techniques (Colposcopy, Direct Visual Inspection, and Spectroscopic 
and other Visual Methods ). They found that the simple visual screening 
methods are being evaluated as an alternative to cytology in low-resource 
settings where screening using cervical cytology is not feasible. However, 
multiple studies have shown Direct Visual Inspection ( DVI ) to have a 
significant sensitivity . 
Catterina Ferreccio and co-workers ( 50 )   performed a study on  a 
Comparison of Single and Combined Visual, Cytological, and Virologic 
Tests as Screening Strategies in a Region at High Risk of Cervical 
Cancer. Here, its also deduced that the study is relevant to my subject in 
question.A study was carried out for the performance of the acetic acid 
test when used in field conditions as a screening test for cervical cancer. 
This is relevant to my work  for application of such test in low resource 
areas in Sudan and other developing world.  [Trop Med Int Health. 2003]  
Another work was done on Visual inspection with acetic acid and 
cytology in the early detection of cervical neoplasia in Kolkata, India. 
[Int J Gynecol Cancer. 2003]. In addition to this a similar study was 
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performed on the assessment of two cervical screening methods in 
Mongolia: cervical cytology and visual inspection with acetic acid. [J 
Low Genit Tract Dis. 2006]  
A study was also done on visual inspection of the uterine cervix after the 
application of acetic acid in the detection of cervical carcinoma and its 
precursors. [Cancer. 1998] . This is very relevant to my work and is 
typical in unequipped centers. 
A study in Cameroon similar to mine by A. Doh, F. Essimbi and 
colleagues  ( 51 ) on visual inspection with acetic acid and cytology as 
screening methods for cervical lesions . VIA has acceptable test qualities 
and may in low resource settings be implemented as a large scale 
screening method. 
In 2007, A group of clinicians also studied the comparison of visual 
inspection and Papanicolaou (PAP) smears for cervical cancer screening 
in Honduras: should PAP smears be abandoned? [Trop Med Int Health. 
2007] They found that VIA was more sensitive than Pap smear, but the 
latter is more specific than VIA. 
Shinji Sato et al,  ( 52 )  did a case study on the effectiveness of mass 
screening for cervical cancer with the cytologic smear in Japan. It was 
found that the odds ratio of invasive cervical cancer for the previously 
screened versus unscreened was significant. This case-control study 
statistically showed the usefulness of screening for cervical cancer in 
Japan. Consequently, doing such study here in Sudan can play a great role 
in the quality of health care in our nation.   
In 1982, Ottaviano and La Torre ( 53 ) published an important study 
involving 2,400 women who were examined visually and colposcopically 
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after a Cervical wash with acetic acid. A key result was that "naked-eye" 
(Unmagnified) inspection detected abnormalities in 98.4% of the cases 
(i.e. in 307 of 312 patients assessed colposcopically as having an 
abnormal transformation zone). In addition, (unmagnified) visual 
inspection with acetic acid (VIA) identified 98.9% of the cases as normal 
(i.e., in 1,568 of 1,584 women diagnosed as normal by Colposcopy). 
These authors concluded that "colposcopic magnification is not essential 
in clinical practice for the identification of the cervix ‘at risk’" (Ottaviano 
and La Torre 1982). 
Subsequently, Abrams at el (54) published his experience with the 
"Gynoscope," a monocular telescope with a magnifying power of 2.5, 
which he developed as an adjunct to cytological screening (Abrams 
1990). In that study, Abrams reported a high correlation between the 
(visual) Gynoscope examination and cytology (supplemented by biopsy 
results in a few cases). His findings suggested that the use of a low-power 
device could provide excellent results as an adjunct to cytology and 
"should be considered as a practical adjunct that will encourage better 
sampling by the clinician . . [and] alert the pathologist to the presence of a 
suspicious lesion."  
Two more recent studies also demonstrated that visual inspection of the 
cervix can be helpful in reducing referrals for Colposcopy without 
compromising quality of care (Frisch, Milner and Ferris 1994; 
Slawson, Bennett and Herman 1992). For example, Slawson et al ( 55) 
found that among women who eventually had an abnormal biopsy, VIA 
detected disease in approximately 64% of such cases, a very similar rate 
to what they found for the Pap smear (68%). In addition, as the 
investigator became more experienced, positive predictive value 
improved by almost 30%. Thus they concluded that "[VIA] is a safe, 
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simple and effective adjunct to the Papanicolaou smear for cervical 
cancer screening."  
Likewise, Frisch et al ( 56 ) discovered that using VIA as an adjunct to 
cytology improved both the number of dysplastic lesions found as well as 
the negative predictive value of cytology (that is, if the Pap smear and the 
visual inspection both were normal, Colposcopy and biopsy were also 
more likely to be normal than if just a Pap smear was performed alone ). 
Even though the studies described above all contributed to demonstrating 
the potential value of visual inspection of the cervix as a screening 
approach, evidence from more rigorous scientific studies was needed 
before clinicians would accept visual inspection as an alternative to 
cytology as a primary screening approach—even in settings where Pap 
smear-based services are not possible (Franco and                  
Monsonego. ( 57 )  
To this end, the World Health Organization (WHO) supported a study in 
India between 1988 and 1991 in which unmagnified visual inspection 
with acetic acid washing was evaluated as a "down staging" technique.    
( 58 )The results of this study showed VIA to be effective in identifying 
women with cancer at an earlier, more treatable stage (Singh, Sehgal 
and Luthra 1992).  
Many comparative studies have been done which suggest that the efficacy 
of  VIA is comparable to that of cytology. In 1999 the University of 
Zimbabwe and the JHPIEGO ( 4 ) published the results of their project 
involving 10 934 patients and found that VIA was more sensitive but less 
specific than cytology. The sensitivity for VIA was 76.7% (95% CI. 70.3-
82.3) and that for cytology was 44.3% (95% CI, 37.3-51.4). The 
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specificity for VIA was however less than that for cytology (64.1% 
versus 90.6%).  
Denny L at el. ( 59 ) in South Africa also reported favorable findings 
after the examination of 2944 people aged between 35 and 65 years. The 
same authors ( 59 ) published in 2002 after studying 2754 patients their 
confirmation of the VIA test as a primary screening test for low resource 
areas. In the last test they indicated the sensitivity for VIA (without 
magnification) for HSIL as 70% with a specificity of 79%. 
(Magnification did not significantly improve the sensitivity). In rural 
China, after examining 1997 patients, Belinson et al in 2001 ( 60 ) 
showed a sensitivity of 71% for HSIL with a specificity of 74%. They 
concluded that the sensitivity of VIA equaled or exceeded reported rates 
for conventional cytology. In his article ‘Costs and Benefits of Different 
Strategies To Screen For Cervical Cancer In Less-Developed Countries’ 
Mandelblatt explains the cost-effectiveness of VIA ( 60 ). From the 
foregoing VIA has everything to recommend it for routine use for low 
resource settings even though patients with false positive results still have 
to bear extra costs of hospital treatment or stand the risk of cryotherapy of 
their otherwise normal cervices. 
In 1994 another study was conducted in South Africa involving visual 
screening and Pap smears, performed in a mobile unit equipped to 
process  smears on site. A gynecologist performed Colposcopy to confirm 
disease in the mobile unit either immediately or within a couple of days 
after screening. The positive predictive value for VIA was found in this 
investigation to be similar to that of the Pap smear and the authors thus 
concluded that "naked-eye visualization of the cervix after application of 
diluted acetic acid . . . warrants consideration as an alternative to 
cytologic screening" (Megevand et al . ( 61 ) 
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 Finally,     in    a    recent    1997     publication,   Franco  and 
Monsonego (  57 )described their experiences with women who had 
reported to an early cancer detection center in India for opportunistic 
cervical cytology and agreed to participate in a study to evaluate unaided 
visual inspection, cervicoscopy and cytology (Franco and Monsonego 
1997). Preliminary results of this study indicated that, compared to 
cytology, VIA was more sensitive in detecting lesions although the 
difference was not statistically significant. In this study, however, the 
specificity of cytology was statistically significantly higher than that of 
VIA.  
Finally, the findings or preliminary results of four recent or ongoing 
studies on visual inspection in Indonesia, Kenya, Zimbabwe and South 
Africa  ( 62 ) provide supportive additional information. These studies 
seek to answer the basic research question: "What are the test qualities of 
visual inspection as a primary screening modality?" Most of these studies 
also address the more specific question of whether visual inspection is 
"acceptably" effective in distinguishing diseased from non diseased 
persons in a particular healthcare setting by comparing the test qualities 
of visual inspection with other screening tests (e.g., Pap smears) 
performed under the same conditions.  
While it is too early to draw conclusions from ongoing studies, 
preliminary or final results from the comparative studies suggest that 
visual inspection with acetic acid performs comparably to the Pap smear 
and/or other screening tests being investigated in those settings. Once the 
two ongoing studies are completed, these results should provide the 
additional evidence needed to support clinicians in their decisions 
regarding the use of visual inspection as a primary screening approach 
among the cytology and colposcopic approaches. 
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These observations confer some credibility to the suggestion that there is  
great need to review these screening diagnostic tools in our country 
(Sudan). 
In the Gynecologic oncology conference conducted in 2007,  Nigeria,      
( 63 )  it was reported that Screening programs have been shown to be 
highly effective in developed countries, helping to reduce death due to 
cervical cancer in the United States by 74% between 1955 and 1992( 63 ). 
These programs rely on cytological techniques such as the Papanicolaou 
smear often followed by magnified visual inspection with a Colposcope 
and biopsy of abnormal appearing areas. Cytologic screening and 
Colposcopy are often ill suited for developing countries, however, 
because of their relatively high cost, substantial need for infrastructure, 
trained personnel, and the long time between when testing occurs and 
when results are available. With this in mind, new approaches to 
screening in developing countries have focused on technologies with 
minimal resource needs such as visual inspection with application of 
acetic acid (VIA) and visual inspection with Lugol's Iodine (VILI). It has 
been projected that screening even once in a lifetime with VIA can lead 
to a 25% reduction in the lifetime risk of cervical cancer in developing 
nations. In low-resource settings, estimates of the accuracy of VIA vary 
widely, with reported sensitivity ranging from 90.1% to 55% and 
specificity from 92.2% to 65%.  
In a study in Kinshasa, Congo of 1528 woman, it was found that 
physicians using VIA achieved both a higher sensitivity and specificity 
for detection of disease as compared to nurses, highlighting the 
importance of provider experience and training. Additionally, it is 
generally agreed that VIA has a higher sensitivity than cytology for 
detecting high grade lesions but a lower specificity. The variations in 
accuracy of VIA lead to concerns about its reproducibility. The potential 
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for a high number of false-positive results raises concerns about over 
treatment in resource-poor environments. Magnified visual inspection 
with Colposcopy and application of acetic acid can improve specificity, 
but its use is limited by the cost of a Colposcope. A low-cost device that 
provides easy to interpret images of the cervix with a higher specificity 
than VIA may lead to more effective cervical cancer screening in low-
resource settings. Several groups have developed magnified optical 
imaging devices which mimic the operation of the Colposcope at a 
reduced cost and in some instances with the added ability to  
capture and save images. Cremer et al. used a simple commercially 
available digital camera in El Salvador and noted higher sensitivity than 
with VIA ( 64 ). Walmer et al. developed a battery powered Colposcope 
suitable for low-resource settings. ( 65 ) The Program for Appropriate 
Technology in Health (PATH) has developed the AviScope™ which uses 
LED illumination and provides 4× magnification. These devices are 
promising, but need further development and testing in larger clinical 
trials to compare their effectiveness to Colposcopy, VIA, and VILI.  
To date, there are no or little informative data about cervical carcinoma .  
Such data if available might provide a basis for better quality of easy  
diagnosis and management. 
 
1.16.The Principle Procedures of the Comparative 
Diagnostic Studies as VIA, Cytology and Colposcopy. 
1.16.1. History of Research on Visual Inspection 
Historically, before the advent of Pap smears and 
programmatic screening, healthcare providers relied on 
looking at the cervix to detect abnormalities. Schiller test – 
48 
 
has been used for many years (to aid in differentiating 
"mature" normal from "immature" abnormal epithelium).  
After the 1950s, when the Pap smear became the standard for cervical 
cancer screening. Increasing numbers of women undergoing this test led 
to increased utilization of the colposcope (initially developed in the 
1930s) to confirm screening findings. 
Years later, given the expense and inconvenience of colposcopy services, 
clinicians began to explore whether unmagnified visualization of the 
cervix (with acetic acid) could be used as an adjunct to cytology so that 
patients in need of colposcopy could be identified more effectively and 
efficiently. 
However few studies were conducted, that examined the value of 
unmagnified inspection of the cervix after the application of acetic acid 
(VIA) for purposes of identifying a normal "transformation zone" or 
detecting precancerous lesions of the cervix (i.e., primary screening). 
Then, in 1982, Ottaviano and La Torre published an important study 
involving 2,400 women who were examined visually and colposcopically 
after a cervical wash with acetic acid. "naked-eye" (unmagnified) 
inspection detected abnormalities in 98.4% of the cases (i.e., in 307 of 
312 patients assessed colposcopically as having an abnormal 
transformation zone).These authors concluded that "colposcopic 
magnification is not essential in clinical practice for the identification of 
the cervix ‘at risk.’" 
In 1990, Abrams published his experience with the "Gynoscope," a 
monocular telescope with a magnifying power of 2.5, high correlation 
between the (visual) Gynoscope examination and cytology. “should be 
considered as a practical adjunct that will encourage better sampling by 
the clinician”.  
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World Health Organization (WHO) supported a study in India between 
1988 and 1991 in which unmagnified visual inspection with acetic acid 
washing was evaluated as a "down staging" technique. VIA was found to 
be effective in identifying women with cancer at an earlier, more treatable 
stage.  
Several other comparative studies in Kenya, Zimbabwe and South Africa 
suggest that visual inspection with acetic acid performs comparably to the 
Pap smear and/or other screening tests.  
More recent studies have also demonstrated that "VIA is a safe, simple 
and effective adjunct to the Papanicolaou smear for cervical cancer 
screening” and can be helpful in reducing referrals for colposcopy 
without compromising quality of care.  
 
1.16.1.1. The principle behind Aceto-whitening 
Acetic acid causes dehydration of cells and coagulation of cellular 
protein; thereby reducing the transparency of epithelium that appears 
white. These changes are more pronounced in abnormal epithelium 
because of higher concentration of proteins (increase nuclear protein and 
chromatin material) in the dysplastic cells.3 It is possible to recognize 
acetowhitening of the dysplastic cervical epithelium with the naked eye, 
and this constitutes a positive VIA test. (53)  
Normal squamous epithelium is light pink in colour and the columnar  
epithelium is red. CIN lesion, if present will appear as a dense-white 
opacity that abuts the squamocolumnar junction and this constitutes a 
positive test result (International Agency for Research on Cancer). The 
aceto-white appearance is not unique to CIN and cancer. It is also seen in 
other conditions when increased nuclear protein is present; as in healing 
and regenerating epithelium (associated with inflammation and erosion),  
immature squamous metaplasia and leukoplakia. But such inflammatory  
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acetowhitening are patchy, ill defined, not restricted to the transformation  
zone and quickly disappear (within a minute). On the other hand, the  
acetowhite of CIN is dense and opaque with well-demarcated margins 
and occupies the transformation zone. The opaque whitening in CIN 
appears instantaneously and reverses much more slowly, lasting for 3-5 
minutes.  
1.16.2. Cervical Cytology 
The Pap smear is Cervical cytology which was introduced by George  
Papanicolaou into clinical practice in 1940.  In 1945, the Papanicolaou  
smear received the endorsement of the American cancer society as an  
effective method for the prevention of cervical cancer. It is a powerful  
diagnostic tool for detecting cancerous and precancerous cervical lesions.  
The Pap test smear has been credited with reducing mortality from 
cervical cancer by as much as 70%. (Papanicolaou GN. Introduction of 
Pap smear in early detection of cervical malignancies. Am J Clin Path 
1940; 19: 301-8.  ) 
Traditionally the cervical specimens have been taken by wooden or 
plastic spatulae or brushes but in my work I was using wooden spatulae. 
The specimen is then smeared on a glass slide and fixed immediately with 
95% alcohol for duration of 15 to 30 minutes or more. Pap staining 
process will then take place. 
 
1.16.2.1. Pap Staining Procedure: 
The Pap test involves a staining method. This staining method includes a  
polychromatic reaction which seeks to display the many variations of  
cellular morphology to show degrees of cellular maturity and metabolic  
activity.  
The four main steps of the Pap test staining method are:  
(1) Slide fixation, 
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 (2) nuclear staining with Haematoxylin,  
(3) cytoplasmic staining, generally with counterstains orange G and EA,   
(4) clearing and mounting. 
  
1.16.2.2. The procedure is taken as follows: 
-The Slide smear specimen is fixed in 95% Alcohol for about 30 minutes 
-The slide specimen is then hydrated by dipping in water bath for about 
10-15 seconds 
-This is dipped into Harris Haematoxylin stain for 2-3 minutes 
-The slide is then hydrated again for 10-15 seconds 
-This is followed by dipping of the slide specimen into the counterstain 
EA-40 for up to two minutes 
-Dehydration of the stained slide specimen in alcohol in three sequential 
steps as Alcohol 95%, then Alcohol 100% twice for 10-15 seconds 
-This is finalized by rinsing the slide with water and mounting using DP 
wax and the slides allowed to dry 
-The stained slide specimen can then be read using the Olympus Light 
Microscope.  
-The Pap cytology report is then written.   
 
1.16.3. COLPOSCOPE 
The Colposcope is a thin, flexible tube with a magnifying device that  is 
inserted into the vagina. The Colposcope allows the doctor to visually 
examine the cervix.  
 
1.16.3.1. Colposcopy History 
Early 1920’s--Hinselmann in Germany started to work colposcopy. In  
1925 he invented a Colposcope. Several scientist contributed a lot to 
colposcopy and its used in gynaecological practice. In 1929 Levy 
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increased magnification of this instrument. Emmerit introduced  it to 
United States in 1931 and by 1954, Bolten moved to New Orleans and set 
up first Colposcopic Clinic. In 1964 American Society for Colposcopic 
and Cervical Pathology was established. Following this, in 1991 Bethesda 
System of classification was introduced. Ten years later (2001),  Bethesda 
II Revised Nomenclature. 
Colposcopy continues to evolve with improvements in Pathologic criteria 
and defined treatment protocols. 
 
1.16.3.2. Indications for Colposcopy 
1. Pap with dysplasia or Cancer 
2. Pap with unexplained atypia 
3. Pap with HPV 
4. Suspicious visible lesion on cervix 
5. History of DES Exposure 
 
1.16.3.3. Strong Consideration for Colposcopy 
1. Visible Condyloma 
2. History of Genital Warts 
3. Unexplained vaginal discharge, vulvodynia 
4. Sexual partner with condyloma 
5. History of current STD’s 
6. Multiple Sexual Partners 
 
1.16.3.4. Contraindications to Colposcopy 
1. Active GC or Chlamydia 
2. Non cooperative patient 
3. Pregnancy precludes ECC but biopsy is permissible 
4. Heavy Menses 
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1.16.3.5. Basic Satisfactory Requirements of Colposcopic Exam 
1.  Adequate Visualization 
2. Entire TZ Zone seen 
3. Abnormal areas seen in entirety 
4. Endocervical Canal free of Dysplasia 
5. No Evidence of Invasive Cancer 
6. Abnormal Areas Biopsied 
7. ECC Completed (Non-Pregnant patients) 
 
1.16.3.6. Procedure: 
Patient was laid in lithotomy position and oil or Vaseline cream   
moistened sterile speculum was inserted. Then 5% acetic acid was  
applied to the cervix and left for up to 1-3 minutes. 
Primary observation of the changes on the cervical surface was  
performed with low magnification (X5) to enhance the view of the  entire 
cervix and vagina. Then, this region was re-evaluated with high 
magnification (X40). The acetic acid solution makes abnormal cells stand 
out more clearly against the surrounding tissue.  
When a Colposcopy is performed, a cervical  punch biopsy was  
done at the same time for some cases with positive Aceto-white  and 
suspicious areas and the specimen fixed and sent for further  
histopathological evaluation.   
During my work study, I was doing the Pap whereas colposcopist and 
biopsies are done by gynecologist who was my Co-supervisor.  
 
1.16.3.7. Colposcopic findings,( Iranian journal of Pathology, 2006 ): 
1.16.3.7.1.Aceto-white epithelium: 
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Acetic acid does not affect mature colposcopic findings. It has been also 
found that Acetic acid does not affect the mature glycogen-producing 
epithelium, because the acid does not penetrate below  the upper 1/3 of 
the epithelium. The cells in this region have very small nuclei and a large 
amount of glycogen (not protein). These areas appear  pink during 
Colposcopy. Dysplastic cells which are most affected, turn to white. They 
contain large nuclei with abnormally large amount of chromatin (protein). 
The columnar villi become plumper, therefore SCJ become easier to be 
observed. They appear slightly white, particularly in the presence of 
metaplasia.  
The immature metaplastic cells have large nuclei and also show some 
effects of acetic acid, but they are not as white or opaque as CIN, but  
instead appear gray and filmy.  
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1.16.3.7.2: Punctuation:  
This term refers to dilated capillaries terminating on the surface which 
appear from the ends as a collection of dots. When these vessels occur in 
a well- demarcated area of acetowhite epithelium, they indicate an 
abnormal epithelium, most often CIN.  
1.16.3.7.3: Mosaic pattern:  
Terminal capillaries surrounding roughly circular or polygonal shaped 
blocks of aceto-white epithelium crowded together are called mosaic, 
because their appearance is similar to mosaic tile. Mosaic pattern tends to 
be associated with higher-grade lesions, i.e. CIN2 and CIN3.  
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1.16.3.7.4: Atypical vascular pattern:  
These patterns are characteristic of invasive cervical cancer and include 
looped vessels, branching vessels, and reticular vessels.  
1.16.3.7.5: Leukoplakia:  
This is a white epithelial plaque, visible before application of acetic acid. 
A layer of keratin on the surface of epithelium causes it. Keratin 
production is abnormal in cervicovaginal mucosa. Several factors  
can cause leukoplakia including HPV, keratinizing CIN, keratinizing  
carcinoma, chronic trauma from diaphragm, pessary, or tampon, and  
radiotherapy. Such areas should undergo biopsy to rule out keratinizing  
carcinoma.  
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1.17:  JUSTIFICATION 
In the literature there is great concern to diagnose cervical carcinoma 
very early at the preclinical stages to improve the prognosis for treated 
cases.  
In Sudan, cervical carcinoma is the second most killer cancer, next to 
breast cancer by 18% (WHO report, Sudan, 2007). There is no report 
about this from South Sudan. 
In  Sudan, comparative studies in the diagnosis of this condition between 
VIA, PAP smear and Colposcopy as screening tools have not been done, 
so it would be essential to perform this work to let clinicians be aware of 
them for the management and quality of patients care. 
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1.18: OBJECTIVES 
1.18.1: GENERAL OBJECTIVES : 
To study the different types of screening methods available and their 
efficacy as well as to find which of them may be more useful in low 
resource settings here in the Sudan . 
1.18.2: SPECIFIC  OBJECTIVE : 
 (1) To identify preclinical stages that are potentially curable. 
(2)  To identify cost-effective use of health care resources in the various 
         types of screening methods available.  
(3)  To improve the prognosis for treated cases. 
(4)  To reassure those with negative tests. 
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1.19: RESEARCH LIMITATIONS 
 
1.Presence of severe cervical infections may lead to false positive VIA 
and PAP smear results 
2.Technical inexperience personnel in reading PAP smear and examining 
colposcopy  
3.False reassurance of those with false-negatives 
4.Unnecessary morbidity for those with false positives 
5.Uncertainty concerning appropriate treatment of early lesions of 
uncertain long term prognosis 
6.Competing priorities of screening activities in use of limited health care 
resources 
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CHAPTER TWO 
METHODOLOGY 
 
2.1: Subjects: 
2.2: Study design: 
This is a cross-sectional comparative study in a form of an  
opportunistic screening program .It is designed to evaluate the validity of 
Pap smear, Colposcopy and  visual inspection of cervix using  acetic acid 
in the diagnosis of cervical lesions in women of reproductive age.   
2.3. Study Area: 
An analytical and descriptive study has been conducted at the centers of  
cervical screening programs in Khartoum . The study has taken  place at 
Saad Abu Al Ellah Teaching Hospital  and  Sudanese - German fertility 
center in Khartoum, a private health facility.  
2.4. Study duration: 
Data has been collected since November 2008 through August 2009 and 
most of the samples were collected from Saad Abu Al Ellah Hospital. 
The remaining data were taken from Sudanese- German fertility center in 
Khartoum. Overall time period is ten months.  
2.5. Study Population: 
The study population included patients who come voluntarily or are 
referred  from other hospitals or private clinics to the screening centers. 
About 60-100 patients including controls were supposed to be studied  
but due to the technical inconveniences at the Saad Abu Al Ellah and 
Omdurman Maternity hospitals,  data collection became difficult. So 
some data were collected from the Sudanese-German Fertility Center. 
Consequently, about thirty-one patients  were studied.  
 
2.6.Inclusion Criteria: 
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Any woman in the reproductive bearing age who attended to the center  
between the ages of 16 to 55 years including unmarried ladies who have  
already practice sexual intercourse. Volunteers and referred patients  
inclusive. 
 
2.7.Exclusion Criteria: 
1-Patients less than 16 years 
2-Those patients who refused the test 
3-Clinically frank cervical malignancy 
4-Patients who are in menopause 
 
2.7.Tools and methods: 
2.7.1. Consent :  
 
 Informed and written consent was sought in from research participants. 
Formal approval for the study was obtained from the Saad Abu El Eillah 
Teaching Hospital and Sudan-German Fertility Center administrations. 
Confidentiality shall be maintained in accordance with regulations of 
medical practice. 
 Results of the test were reported to the patients, and those who showed 
positivity were treated and those with negative results were reassured. 
English and Arabic versions of the consent are available in the appendix. 
 
2.7.2: Sampling Technique: 
Simple random sampling was utilized in study. 
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2.7.3: Questionnaire:   
Almost all cervical cancers are caused by human papillomavirus 
(HPV), a common virus that can be passed from one person to 
another during sex. There are many types of HPV. Some HPV types 
can cause changes on a woman’s cervix that can lead to cervical 
cancer over time, while other types can cause genital warts. 
HPV is so common that most people get it at some time in their 
lives, but HPV usually causes no symptoms so you can't tell that 
you have it. For most women, HPV will go away on its own; 
however, if it does not, there is a chance that, over time, it may 
cause cervical cancer. 
In addition to HPV, other things can increase your risk of cervical 
cancer. They include— 
1. Not having regular Pap tests. 
2. Not following up with your doctor if you had a Pap test result 
that is not normal. 
3. Having HIV, the virus that causes AIDS or another condition 
that weakens your immune system (making it hard for your body 
to fight off health problems). 
4. Other risk factors include smoking, age, sexual behavior, 
Chlamydial infections, diet, oral contraceptive pills, drugs, DES, 
low socioeconomic status, family history of cervical cancer, 
multiparity and genetic factors. 
See appendix for details. 
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2.7.4: Apparatuses: 
2.7.4.1: COLPOSCOPY APPARATUSE: 
1. Non-medical materials: 
Office table-chairs-fridge-stools-dustbin-file cabinets, stationeries 
 
2. Medical Materials: 
Colposcope, Gynaecological chair, Couch, Curtain Screen, Dressing 
trolley, Dressing tray, Spot light, Oven, Sterilization drums ( large, 
medium, small ), Linens, Stethoscope and Sphygmomanometer, Kidney 
dishes, Sterile containers, Cusco’s speculum, Sims speculum, Vaginal 
retractors, Punch biopsy forceps, Gunsberg forceps ( endometrial ), 
Uterine biopsy curette, Uterine sound, Tubular curette, Wooden cervical 
spatula, Cotton swabs, Sterile wooden swabs, Formalin solution, Acetic 
acid, Povidone iodine, Silver nitrate solution, Physiological saline, 
Potassium Hydroxide ( KOH ), Sterile gauze, Mineral oil, Vaseline 
cream. 
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 COLPOSCOPE 
 
 
Fig. 2.1 
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Fig.2.2. 
2.7.4.2:  CYTOLOGY (PAP SMEAR) MATERIALS: 
Light microscope ( Olympus X40 ), Stop watch, Microscope slides with 
ground edges, Cover glass, Pap Stains  ( Harris Haematoxylin, EA-40 ), 
Ethyl ( absolute ) alcohol 95%, Xylene, DPX mounting media, Gloves, 
Slide marker, Slide storage cabinet, Cotton, Filter paper, Conu jars, Rags, 
Distilled water, Electricity cable source, Tap water, Stationeries. 
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2.7.5: Clinical Examination: 
Proper gynecological, obstetric and medical history will be taken and the  
patient will be examined systematically. All findings documented in the  
Questionnaire. 
2.7.6: Sample Collection and Procedure: 
With the patient in the lithotomy position Sims vaginal speculum is 
inserted and fixed. Cleaning of the vaginal canal and ectocervix takes 
place. With the help of sterile cotton wool, 5% Acetic acid solution is 
applied on to the cervical area after being soaked in cotton wool. After 1-
3 minutes, the cervix is then visualized. 
Visual inspection with acetic acid could identify abnormal acetowhite  
changes.  
Following this, a Pap smear is then performed 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
CHAPTER   THREE 
RESULTS 
 
 Thirty one patients were studied . The characteristics of study population 
includes only women in the reproductive age range in the Sudan. These 
characteristics include:  
.Mean age of women 37.06, Range 16 – 55 years 
.Mean age at Menarche 13.23, Range 12- 16 years 
.Mean age at Marriage 15.76, Range 0.7 years ( 7 months )- 40 years 
.Mean age at First Pregnancy 21.19, Range 12-32 
.Mean age at Last Pregnancy … Omitted 
.Mean Parity … omitted 
.Clinically healthy Cervix 15, percentage 48.39 % 
.Clinically unhealthy Cervix 16, Percentage 51.61 % 
 
Table: 3.1. 
Distribution of Studied Group According to Age 
 Frequency Percent 
 20-30 9 29.0 
  31-40 14 45.2 
  41-50 6 19.4 
  More than 51 2 6.5 
  Total 31 100.0 
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Figure: 3.1.  Age Distribution of the Studied Group 
 
 
Table : 3.2. 
 Distribution According To Menarche 
Years  Frequency  Percent 
12yr  5  16.1 
13yr  18  58.1 
14yr  5  16.1 
15yr   2  6.5 
16yr  1  3.2 
Total   31  100 
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Figure:3.2.  Distribution of the Group According Menarche 
 
Table : 3.3. Distribution According to Application of Hormones / 
OCP, and  IUCD 
  
Frequency 
(Yes) 
Percent 
(Yes) 
Frequency 
(No) 
Percent 
(No) 
Hormonal/ 
Contraceptive 
Pills  used  14  45.2  17  54.8 
IUCD used 
  6  19.4  25  80.6 
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Figure: 3.3.  Distribution According to Application of Hormones, OCP, 
and IUCD  
 
 
Table : 3.4. 
 Distribution According to the Main Symptomatology 
  Frequency (Yes)
Percent 
(Yes) 
Frequency 
(No) 
Percent 
(No) 
Vaginal discharge  26  83.9  5  16.1 
AVB  16  51.6  15  48.4 
Pelvic pain  21  67.7  10  32.3 
UTI  16  51.6  15  48.4 
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Figure: 3.4. Distribution According to the Main Symptoms 
 
 
 
 
Table: 3.5.  
Distribution of Colposcopy Findings According to Studied Age 
Group 
Age( 
yrs ) 
Ecto
py 
Norm
al 
Aceto 
white 
Punctu
ation 
Mo
saic
Meta
plasia 
Vascu
lar 
Inflam
mation 
Total 
 20-30  7 2 1 0 1 3 0 2 16 
31-40  12 1 2 0 0 4 0 1 20 
41-50 2 0 0 1 3 2 0 0 8 
>51 0 0 0 0 0 1 1 0 2 
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Figure: 3.5. Distribution of Colposcopy Findings According to 
Studied Age Groups 
 
Table : 3.6.  Distribution of  Miscellaneous Colposcopic Findings 
 Frequency Percent 
  Ectopy 16 51.6 
Mosaic Pattern 3 9.7 
Metaplasia 3 9.7 
Granular 1 3.2 
Normal 1 3.2 
Smooth Cx 1 3.2 
Healthy 1 3.2 
Vascular, friable Cx 1 3.2 
Punctuation 1 3.2 
Candidiasis 1 3.2 
A.W patch 1 3.2 
Contact Bleeding 1 3.2 
Total 31 100.0 
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Figure: 3.6. Distribution of Miscellaneous Colposcopy Findings 
 
Table: 3.7. Results of Cytological Examination versus Specific 
Cervical Conditions 
Pap  Smear  Results Number Percentage ( % ) 
Normal ( Pap I ) 12 30 
Inflammatory/Infection ( Pap II ) 12 30 
CIN  I  ( Pap III ) 7 17.5 
CIN  II  (Pap IV ) 4 10 
CIN  III  ( Pap V ) 1 2.5 
Invasive   Cx. Cancer ( Pap VI ) 1 2.5 
Others(VII),Specify(Squam metaplas)  3 7.5 
Total 40 100 
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Figure: 3.7. Results of Cytological Examination versus Specific 
Cervical Conditions 
 
Table: 3.8. Distribution of Normal Cytology results. 
   Frequency  Percent 
Yes   12  38.7 
No   19  61.3 
Total   31  100 
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Figure : 3.8 Distribution of Normal Cytology Results Versus 
Abnormal 
 
Table : 3.9.  Distribution of  Cytology Results, Inflammation/ 
Infection 
   Frequency   Percent 
Yes   12  38.7 
No   19  61.3 
Total   31  100 
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Figure: 3.9.  Distribution of Inflammatory Cervical Conditions 
 
Table: 3.10.   Distribution Of  CIN I in the Studied Population 
   Frequency  Percent 
Yes   7  22.6 
No   24  77.4 
Total   31  100 
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Figure: 3.10.  Distribution  of  CIN I 
 
 
 
Table: 3.11. Distribution of CIN II 
   Frequency   Percent 
Yes   4  12.9 
No   27  87.1 
Total   31  100 
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Figure: 3.11  Distribution  of  CIN II 
 
 
 
 
Table: 3.12.  Distribution CIN III 
   Frequency   Percent 
Yes   1  3.2 
No   30  96.8 
Total   31  100 
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Figure: 3.12.  Distribution of CIN  III  
 
 
Table: 3.13. Distribution of  Invasive Cervical Carcinoma 
   Frequency  Percent 
Yes   1  3.2 
No   30  96.8 
Total   31  100 
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Figure: 3.13. Distribution of invasive Cervical Cancer 
 
Table: 3.14. Distribution of Final diagnosis, normal Results  
 
   Frequency  Percent 
Yes   12  38.7 
No   19  61.3 
Total   31  100 
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Figure: 3.14.  Distribution of Final diagnosis, normal ResultsTable:  
 
3.15. Distribution Final Diagnoses, Cervicitis  
 
   Frequency  Percent 
Yes   11  35.5 
No   20  64.5 
Total   31  100 
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Figure: 3.15. Distribution of Cervicitis in the Studied population 
 
Table: 3.16. 
 Distribution of CIN I, CIN II AND CIN III in the Studied Group 
 
  
  
Yes  No  
Frequency (Yes)  Percent (Yes)  Frequency (No)  Percent (No) 
CIN‐I  7  22.6  24  77.6 
CIN‐II  4  12.9  27  87.1 
CIN‐III  1  3.2  30  96.8 
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Figure: 3.16  Distribution of Cervical Intraepithelial Neoplasia (CIN) 
 
Table: 3.17. 
 Distribution of Invasive SCC  
 
   Frequency  Percent 
Yes   1  3.2 
No   30  96.8 
Total   31  100 
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Figure: 3.17.  Distribution of  Invasive Squamous Cell Carcinoma 
 
 
Table : 3.18. 
Results of Visual Inspection Using Aceto-Acetic Acid ( VIA ) 
 
Reaction Number Percentage ( % ) 
Mildly ( weakly )  Positive 7 22.6 
Moderately  Positive 00 00 
Severely  Positive 22 70.9 
Negative 2 6.5 
Total 31 100 
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Figure: 3.18. 
 Results of Visual Inspection Using Aceto-Acetic Acid ( VIA ) 
According to the Nature of Reaction 
 
 
Table : 3.19. 
 Distribution of Visual Inspection ( VIA ) 
 
   Frequency   Percent 
Positive   22  71 
Negative   9  29 
Total   31  100 
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Figure : 3.19.  Distribution of Overall  VIA Results 
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CHAPTER FOUR 
DISCUSSION 
 
Distribution of studied group according to age was categorized into four  
groups between 20-30 ( 29.0 % ), 31-40 ( 45.2 % ), 41- 50 ( 19.4 % ) and 
2 ( 6.5 % ) for more than 51 years age (Table 1). 
Here, it is found that most cases of cervical malignancies are found over 
age of 30. (66) This study is observed in mine in which most cases are 
seen between the ages 31-40 years at 45.2%. 
Distribution of studied population according to menarche status as 12 
years ( 16.1% ), 13 years ( 58.1% ), 14 years ( 16.1% ), 15 years ( 6.5% ) 
and 16 years ( 3.2% ). ( Fig. 4 ). 
The mean age at menarche is 13.23 and the common age at menarche is 
13 years. ( Table 2 ). There is no association of menarche with with 
cervical carcinoma. However, it has been found that late menarche is the 
one related with the incidence of cervical carcinoma. ( 67 ) 
However, this study is not seen in my work. 
Distribution of the study group according to the use of hormones, oral 
contraceptive pills and intrauterine device. (Table: 3 ). Here it is clear that  
the use of hormonal drugs and /or contraceptives is related to the genesis 
of cervical cancer at  a frequency of 45.2% compared to IUCD at 19.4%. 
A previous study found that the longer the woman has been on oral 
contraceptives the higher the risk of developing invasive  cervical cancer. 
A woman who has been taking oral contraceptives for five years ( and is 
taking them ) runs approximately twice the risk compared to controls.      
( 68 ).  
In my study, one patient used oral contraceptives for more than four 
years, and all the screening tests used  in the study showed significant 
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results giving cervical intraepithelial Neoplasia. In addition to this, IUCD 
also showed some significant results, but it has been found that there is 
lower risk of association  of IUCD and uterine cervical carcinoma. 
( 69 ). However, some findings showed that IUCDs have no oncogenic 
potential on the uterine cervix. (70)   
Distribution of the study group according to the main symptoms as; 
vaginal discharge 26( 83.9% ), abnormal vaginal bleeding 16 ( 51.6% ), 
pelvic pain 21 ( 67.7% ) and urinary tract infection 16 ( 51.6% ). (Fig.6). 
Unusual vaginal discharge is the most common symptom of cervical 
cancer, but it varies from one woman to another. Pelvic pain that is not 
related to the normal menstrual cycle can be attributed to cervical cancer 
symptoms. Other symptoms like abnormal vaginal bleeding and features 
of urinary tract infections are also common. (71) This presentation is also 
observed in my work with unusual vaginal discharge and pelvic pain 
being present with the highest frequency. 
Distribution of colposcopy findings according to the studied group as ; 
20-30 years ( 16 different findings ), 31-40 years ( 20 ), 41-50 years (8) 
and only two findings for age group of more than 51 years. ( Table 5 ). 
Here , it is clear that cervical Ectopy has the highest frequency and is 
common in the age group 31-40 years. This is the common age group of 
occurrence of cervical cancer. ( Fig. 7 ). 
A study showed that the development of Ectopy is followed by a process 
of metaplasia occurring in the columnar epithelium, known as Squamous 
metaplasia (72, 73 ) 
All women go through this process. Even though cervical Ectopy is a 
physiological phenomenon, it is associated with cervical cancer. 
(74) The frequency of metaplastic changes is also recognized with 32.3%, 
followed by the mosaic pattern, aceto-whitening, inflammatory changes, 
punctuations and vascular changes. Most of these women develop 
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metaplasia in their cervices. A study showed that there is great linked and 
association between metaplastic changes in the cervix and the 
development of invasive Squamous cell carcinoma of the uterine cervix. 
(75) This is observed in my work in that most patients with metaplastic 
changes in the uterine cervix show premalignant cervical lesions 
confirmed by the three diagnostic tools applied in my study. Three studies 
dealing with dealing associations between Ectopy and CIN were 
reviewed. ( 76, 78 ). The study by Sarkar and Steele (77 ) suggested the 
same association and both studies by Mosciki et al ( 76, 78 ). So if it is 
assumed that there is an association between Ectopy and both HPV and 
CIN, and that Ectopy ( a more likely scenario ) rather than these 
conditions favoring the occurrence of Ectopy, then Ectopy should be 
taken to a risk factor for cervical cancer. 
Distribution of results of cytological examination showing specific 
cervical conditions. (Table.7). Some results were more than one in one 
patient . About 30% of the results were found to be healthy, and 70% 
revealed unhealthy uterine cervix. 30% of the findings showed 
inflammatory reactions in the cervix. ( Fig.9). 32.5% expressed cervical 
malignancies in which CIN I ( 17.5% ), CIN II (10%), CIN III ( 2.5% ) 
and invasive cervical cancer i.e. SCC ( 2.5% ). 
Other physiological changes like metaplasia showed ( 7.5% ). 
A study showed that inflammatory lesions in the uterine cervix are 
associated with low grade CIN and probably high grade CIN when the 
cervix is infected by HPV types 16 and 18. Other microorganisms have 
been implicated.(79)  
This is observed in my work with the percentage of 30% of cases are due 
to inflammatory conditions associated with various grades of CIN. A 
previous study showed that the presence of Candida albicans, 
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Trichomonas vaginalis, bacterial vaginosis, Doderlein bacilli, cytologic 
flora and coccoid bacillus were found to be associated with CIN (80). 
From (Table 7), it is found that CIN I ranks top with ( 17.5% ) followed 
by CIN II, then CIN III and invasive cancer. These conditions may 
undergo regression by the help of the immune system. However, CIN I 
may regressed by 60% but may persist by 30%, progression to CIN III by 
10%, and progression to invasion 1 %. The corresponding 
approximations for CIN II are 40%, 40%, 20% and 30% respectively. The 
likelihood of CIN III regressing is 33% and progressing to invasion 
greater than 12%. It is obvious from the above figures that the probability 
of an atypical epithelium becoming invasive increases with severity of 
atypia, but does not occur with every case (81).  
Distribution of the frequency of normal cytology results using Pap Smear 
in the study group. ( Table 8 ). It reflects the status of the uterine as been 
healthy, in comparison to the unhealthy. This is observed in the controls. 
Distribution of the inflammatory cervical conditions in the cytological 
examinations. ( Table: 9 ).This has already been discussed above. 
Distribution of the cytology results CIN I, CIN II, CIN III and invasive 
cancer in the study groups . ( Tables: 10, 11, 12, 13 ) are CIN I (17.5% ), 
CIN II ( 12.9% ), CIN III ( 3.2% ) and invasive cancer ( 3.2% ). 
Relevant discussion has been elaborated above. 
Distribution of the Final Diagnosis of cervical lesions in the studied 
population is verified here as Normal results ( 38.7% ),  Cervicitis            
( 35.7% ), CIN I ( 22.6% ), CIN II ( 12.6% ), CIN III ( 3.2% ), and 
invasive Squamous cell Carcinoma ( 3.2% ) . ( Tables : 14, 15, 16, 17 ). 
CIN I among cervical intraepithelial neoplasias has the highest frequency 
in the studied group. Several studies have been done  and was already 
discussed above. 
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Distribution of  the  results of Visual Inspection  using  Acetoacetic Acid 
( VIA ) according to their nature of the reaction in the studied group as 
mildly or weakly positive ( 22.6% ), moderately positive not observed, 
severely positive ( 70.9% ) and negative reaction ( 6.5% ). ( Table: 18 ). 
Here, it is seen that positive reaction of both characters as mild and severe 
show the highest frequency and both making 93.5%. This is an indication 
that VIA reflects high sensitivity in detecting early cervical malignancies. 
It is also observed  in this study that more women tested positive than the 
cytology. In Seven women with cytological CIN I Six tested positive, all 
the 4 patients confirmed by Pap smear also showed positivity with VIA. 
One patient with CIN III tested negative for VIA, probably due to 
interference with the contact bleeding. It could also be attributed to the 
severe cervical candidiasis that was associated the condition. One woman 
with invasive carcinoma tested positive fro VIA. 
Of the 31 women studied, 29 of them ( 93.5% ) has positive VIA, and 13 
of them ( 41.9% ). VIA positivity varied in the course of the study, some 
mildly positive and the larger group severely positive. In contrast, Pap 
positivity did not vary over the study period. 
Of the 29 patients with positive VIA, 9 of them have Cervicitis. 
With promising sensitivity of VIA test, this is an alternative diagnostic 
technique for developing countries, because it is inexpensive and fast and 
requires a low level of training and no special equipment. Some previous 
reports have  observed that VIA can reach similar or results than the Pap 
smear (4, 61, 82 ) in the detection of CIN. 
In general, the sensitivity of VIA has been shown to be equal to or better 
than the Pap smear while its specificity has been found to lower than that 
of Pap smear. 
Comparing between the diagnostic tools Colposcopy and Pap smear, it 
has been found that considerable variation has been reported in the 
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sensitivity and specificity of cervical cytology, Pap smear is still one of 
the most cost-effective and preventive procedure for screening cervical 
cancer (83,84). At present, the detection of abnormal cervical tissue and 
diagnosis of a disease must be followed by histological examination of 
colposcopy-guided biopsy. Even with optimal conditions, about 5-10% of 
false-negative rate exists in cervical cytology (85,86). According to 
recent data from a review of cervical cytological abnormalities, 
approximately two thirds of false-negative results are caused by sampling 
errors, and the rest are caused by detection errors (84). Sampling errors 
may reflect a situation when abnormal cells are not transferred on the Pap 
smear or when abnormal cells are misinterpreted or missed. The latter can 
explain the importance to have optimal sampling, smearing, fixation and 
staining for reducing sampling errors. If all of these problems are 
contained, then the Pap can be considered to be playing a significant role 
in diagnosis of cervical cancer and its precursors. Pap is found to be more 
specific than sensitive when compared to Colposcopy. The latter is only 
complementary to Pap smear. 
In comparison between Pap smear and VIA, I has been found that   22 out 
of 31 women screened had acetowhite lesions. On pap smear, 13 out of 
the 31 women had  Cervical Intraepithelial Neoplasias and invasive 
cancer. 12 of 31 women showed inflammatory reactions on Pap smear as 
well. The proportion of women screened positive with VIA was 70.9% 
and the proportion of women screened positive with pap smear was 41 %. 
Of the 31 enrolled women, 13 were positive on both VIA and cytology; 
22 were positive on VIA only; and 13 were positive on cytology only.  
patients had cervical biopsies performed on them. Incidence of CIN/ 
cancer cervix in the study population was found to be 41 %. VIA could 
identify 12 out of the 13 CIN/carcinoma cervices; the only lesion being 
missed  by VIA was  CIN III. But VIA had higher number of false 
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positives as compared to cytology. VIA was more sensitive (93.5%) than 
pap smear (41%), which was statistically significant. However, the 
specificity of VIA was lower  than that of cytology . The PPV of VIA  
versus  pap smear were not done as well as the NPV of VIA versus  
cytology due absence of control figures. Overall, VIA demonstrated an 
accuracy of  93.5 % as compared to 41 % for cytology. 
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CHAPTER FIVE 
CONCLUSION AND RECOMMENDATIONS 
Conclusions 
In women undergoing screening for pre-invasive and cancer cervix, 
visual inspection using 5 % acetic acid was found to be more sensitive 
and has a higher accuracy as compared to pap smear. VIA is less specific 
than cytology, resulting in high false-positive and hence unnecessary 
referral for colposcopy/biopsy. Although the present study is small, other 
larger comparative studies have evaluated the validity of VIA as a 
method of cervical cancer screening and concluded the same. Another 
important feature of VIA is its high Negative Predictive Value, which 
means that when the test result is negative, the woman can go home 
assured that she is not likely to have a neoplastic cervical lesion. Visual 
inspection is a simple, accurate, cost effective method of rapidly 
differentiating between a potentially diseased cervix and a healthy one 
and therefore its use can be recommended as primary screening method, 
especially in low resource centre, particularly in developing countries. 
 
Recommendations 
The following recommendations were derived from the various plenary 
discussions:  
1. If morbidity and mortality due to cancer of the cervix are to be 
measurably reduced, cervical cancer screening and treatment 
programs must be implemented for at-risk women on a national or 
large-scale basis.  
2. The test qualities of visual inspection have proven to be reasonably 
consistent across the various investigative studies to date, including 
those for which only preliminary data are currently available. Once 
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ongoing studies are completed, efforts should shift to investigating 
how visual inspection performs in the field under more routine 
health delivery (versus field research) conditions, and how the 
benefits of such visual inspection-based screening programs could 
outweigh program limitations, including the potential for 
overtreatment.  
3. In addition to documenting further the efficacy and safety of visual 
inspection under different field conditions, such applied research 
projects should answer important questions related to the 
practicality, feasibility and, most important, the acceptability of 
visual inspection-based screening programs among the target 
population.  
Large-scale visual inspection-based screening programs should have the 
following characteristics:  
• As a primary means of screening, the use of visual inspection 
should enable the largest proportion of at-risk women to be 
screened at least once during their lives, preferably more 
frequently, if feasible.  
• In our country where cytology programs are not well established 
they should be made to function  in at least as  part of the public 
sector, visual inspection could be used as an adjunct to cytology or 
as the primary means of screening, if desired, to reduce program-
related costs. Confirmation of disease as well as treatment should 
take place at which ever level of the health system which supports 
the least loss-to-follow up, balanced by appropriate treatment.  
• In  our country where cytology programs exist only in the private 
sector, visual inspection could be considered the primary screening 
method in the public sector—with referral for diagnostic testing, if 
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practical, or treatment on the spot if significant loss-to-follow up is 
likely.  
• In Sudan where, in effect, no screening exists in other states , 
visual inspection may be the only feasible option for screening for 
precancerous lesions. Practical ways to increase sensitivity and 
specificity of this test need to be investigated. This could include, 
for example, repeat testing over time or treatment protocols that 
target women most likely to be diseased, given a positive screening 
test (e.g., women with higher parity and/or women over age 30). In 
such settings, treatment would need to be on-the-spot or close 
enough in time and proximity to limit loss-to-follow up.  
      .   There is need to train all young obstetricians and gynaecologist    
the use of colposcopy to be able to diagnose some cases of cervical 
precursor lesions 
      .   Pathology residence should undergo special training in cytology. 
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APPENDIX 
 
UNIVERSITY OF KHARTOUM 
FACULTY OF MEDICINE 
POSTGRADUATE MEDICAL STUDIES BOARD 
DEPARTMENT OF PATHOLOGY 
CONSENT 
Greetings/ Salaam Alaikum ,,,, 
I am a medical doctor and a postgraduate student researcher 
in Clinical Pathology, University of Khartoum. 
My dear……………………………………………………………. 
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I feel grateful to ask you some questions regarding the 
symptoms and signs due to early cervical cancer. It is not an 
examination to you, but only need to know and detect  any 
feature(s) consistent with early changes of premalignant 
cervical conditions. 
Your selected randomly and not targeted with your visit to 
the clinic. 
I will ask you a series of questions and take specimen from 
the cervix for analysis and the clinic will reassure you about 
the results of the test. 
Your answers and results are confidential. Any objection 
from your side will be respected. Your credited for been 
sincere. 
This study will help us to render health care quality services 
to the nation in particular and the world at large. 
DO  YOU AGREE?   YES (     ) ,  NO (    ) 
Sign:_____________________________ 
Date:_____________________________ 
  
 
مﻮﻃﺮﺨﻟا ﺔﻌﻣﺎﺟ  
ﺐﻄﻟا ﺔﻴﻠآ  
 ﻲﺒﻄﻟا ﺲﻠﺠﻤﻟا ﻟ ﺎﻴﻠﻋ تﺎﺳارﺪ  
ضاﺮﻣﻷا ﻢﻠﻋ ﻢﺴﻗ  
  
و ﺔﻘﻓاﻮﻣراﺮѧѧѧﻗا  
  
 ﻲﺗﺎﻴﺤﺗ ﻢﻜﻴﻠﻋ مﻼﺴﻟا /، ، ، ،  
ﻠﻌﻟا تﺎﺳارﺪﻟا ﺐﻟﺎﻃ ﺚﺣﺎﺑو ﺐﻴﺒﻃ ﺎﻧامﻮﻃﺮﺨﻟا ﺔﻌﻣﺎﺟ ، ﺔﻳﺮﻳﺮﺴﻟا ضاﺮﻣﻷا ﻢﻠﻋ ﻲﻓ ﺎﻴ.  
ﺰﻳﺰﻋ ﺎﻳﺗﻲ /......................................................................  
 ﻖﻨﻋ نﺎﻃﺮﺳ ﺐﺒﺴﺑ تﺎﻣﻼﻋو ضاﺮﻋأ ﺔﻘﻠﻌﺘﻤﻟا ﻞﺋﺎﺴﻤﻟا ﺾﻌﺑ ﻢﻜﻨﻣ ﺐﻠﻃﻷ نﺎﻨﺘﻣﻻﺎﺑ ﺮﻌﺷأ
ﺮﻜﺒﻣ ﺖﻗو ﻲﻓ ﻢﺣﺮﻟا .ﻟ ﻂﻘﻓ جﺎﺘﺤﺗ ﻦﻜﻟو ، ﻚﻟ ﺔﺳارد ﻦﻣ ﺲﻴﻟو ﺎﻤﺑ ةﺰﻴﻣ يأ فﺎﺸﺘآاو ﺔﻓﺮﻌﻤ
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  .ﻳﺘﻔﻖ ﻣﻊ اﻟﺘﻐﻴﺮات ﻓﻲ وﻗﺖ ﻣﺒﻜﺮ ﻣﻦ ﻣﺮﺣﻠﺔ ﻣﺎ ﻗﺒﻞ ﺳﺮﻃﺎن ﻋﻨﻖ اﻟﺮﺣﻢ اﻟﻈﺮوف
  .اﺧﺘﺮﺗﻬﺎ ﻋﺸﻮاﺋﻴﺎ ، وﻟﻴﺲ اﻟﻤﺴﺘﻬﺪف ﻣﻊ زﻳﺎرﺗﻚ ﻟﻠﻌﻴﺎدة
وﺳﻮف أﻃﻠﺐ ﻣﻨﻜﻢ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻷﺳﺌﻠﺔ واﺗﺨﺎذ ﻋﻴﻨﺔ ﻣﻦ ﻋﻨﻖ اﻟﺮﺣﻢ ﻟﺘﺤﻠﻴﻠﻬﺎ وﻋﻴﺎدة وأؤآﺪ ﻟﻜﻢ 
  .ﻋﻦ ﻧﺘﺎﺋﺞ اﻻﺧﺘﺒﺎر
  .ﺗﻢ ﺣﺴﺎب اﻟﺨﺎص ﻟﻠﻤﺨﻠﺺ. وﺳﻮف ﺗﺤﺘﺮم أي اﻋﺘﺮاض ﻣﻦ ﺟﺎﻧﺒﻜﻢ. واﻟﻨﺘﺎﺋﺞ ﺳﺮﻳﺔ إﺟﺎﺑﺎﺗﻚ
  وهﺬﻩ اﻟﺪراﺳﺔ ﺗﺴﺎﻋﺪﻧﺎ ﻋﻠﻰ ﺗﻘﺪﻳﻢ اﻟﺨﺪﻣﺎت اﻟﺼﺤﻴﺔ اﻟﺠﻴﺪة ﻟﺮﻋﺎﻳﺔ اﻷﻣﺔ ﻋﻠﻰ وﺟﻪ اﻟﺨﺼﻮص 
  .واﻟﻌﺎﻟﻢ ﺑﺄﺳﺮﻩ
  ____________________________________________________
  
  (    ) ﻻ , (    )هﻞ ﺗﻮاﻓﻘﻮن ﻋﻠﻰ ذﻟﻚ؟ ﻧﻌﻢ 
  
  _____________________________:ﺗﻮﻗﻴﻊ 
 _____________________________:ﺗﺎرﻳﺦ 
  
 
 
 
 
 
 
 
 
 
 MUOTRAHK FO YTISREVINU
 ENICIDEM FO YTLUCAF
 DRAOB SEIDUTS LACIDEM ETAUDARGTSOP
 YGOLOHTAP FO TNEMTRAPED
 
 ERIANNOITSEUQ
 
  YGOLOTYC , YPOCSOPLOC  NEEWTEB SEIDUTS  EVITARAPMOC
 EHT NI  DICA CITECAOTECA   GNISU  NOITCEPSNI LAUSIV DNA
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DIAGNOSIS OF  CERVICAL  MALIGNANCIES  AMONG WOMEN IN 
CHILD BEARING AGE IN  SUDAN 
 
Serial No.  ____________________ 
 
I.PERSONAL  DATA: 
 
1. Name : 
__________________________________________________ 
2. Age ( in years ) :______________ 
3. Occupation : Yes (    ), 
specify________________________________________No (   ) 
4. Religion : i. Muslim (   ) ii. Christian (  ) iii. Others 
(specify)___________ 
5. Marital status: i. Married (  ) ii. Single (  ) iii. Divorced (  ) 
 iv. Widow (  ) v. Others ( specify ) 
_____________________________________________ 
6. Education : i. Basic  (    ) ii. Secondary  (    )  iii. University  (   )                 
iv.  Others(     ) ,                                                                                   
( specify)________________________________________ 
7. Ethnicity : i. Nationality _______________ii.  Country ___________ 
iii. State _________________    iv. Locality ___________________ 
v. Tribe ________________________ 
8.  Current Residence_______________________________________ 
Locality _________________________ 
Contact Address: __________________________________________ 
Contact Tel.____________________     Mobile__________________ 
E-mail :________________________________ 
 
 
II.CLINICAL DATA : 
1.GYNAECOLOGICAL  HISTORY: 
i. Menarche  at ___________ii.  Kata ___________iii. Regular   (    ) 
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iv. Irregular  (    )  v. Dysmenorrhoea   (    ) vi. Others ( specify )___ 
_________________________________________________________ 
2.OBSTETRICS  HISTORY : 
i. Duration  of married__________ii. Gravida ________iii. Para________ 
iv. Abortion :  yes (   )   No  (    )   Specify cause _____________________ 
v. History of hormonal or contraceptives use_______________________ 
_____________________________________________________________ 
vi. History of IUCD use_________________________________________ 
vii. Previous Abnormal Pap Smears 
Done_______________________________________________________ 
viii. Divorce and frequency______________________________________ 
ix. First time of sex ( 1st time of marriage)_________________________ 
x. Multiple sexual partners ( No. of marriages ) ____________________ 
xi. Does the husband have 2nd wife?______________________________ 
 
3.   PAST  MEDICAL   HISTORY: 
i. History of DM________________________________________________ 
ii. History of Hypertension________________________________________ 
iii. History of Allergy ____________________________________________ 
iv. Any Chronic Illness, specify____________________________________ 
v. Past History of STI_______________ specify______________________ 
vi. History of smoking___________________________________________ 
vii. Chronic medication(specify)__________________________________ 
4.  SYMPTOMATOLOGY : 
i. Vaginal discharge (     ) specify__________________________________ 
Duration_______________________ 
ii. Abnormal vaginal bleeding  (    ) ________________________________ 
Duration _____________________________ 
Postcoital ?_________________________________________________ 
iii. Pelvic pain  (   )  __________Duration ___________________________ 
iv. History of UTI  (  )  ____________Duration_______________________ 
v. History of Genital Ulcers  (     )  _________________________________ 
Duration ____________________________________________________ 
vi.  Genital Warts (   )  ___________________________________________ 
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Duration ____________________________________________________ 
vii. Systemic Symptoms : i. Fever (   )  ii. Fatigue (   ) iii. Loss of weight(   ) 
5. CLINICAL  EXAMINATION : 
(a) Examination of external genital area 
Inspections:                 Yes or No 
- Female circumcision------------------------------------------------------------- 
- Condyloma ------------------------------------------------------------------------ 
- Herpetic lesions------------------------------------------------------------------- 
-Others------------------------------------------------------------------------------- 
(b) Examination of the Vagina  and  Cervix 
Procedures :                 Yes or No 
-Inspection with Vaginal Speculum----------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------- 
-Colposcopy---------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------- 
-Visual Inspection with Acetic Acid----------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------- 
-Others ( Specify ) ------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------- 
(c)  Clinical Diagnosis           Yes or No 
- Normal ____________________________________________________ 
-HPV/CIN Signs______________________________________________ 
-Other Infections______________________________________________ 
-Neoplasm/Cancer_____________________________________________ 
6. CYTOLOGICAL  EXAMINATION: 
(a) Pap Smear Performed                   Yes  or No 
Procedure: 
-Cervical brush used____________________________________________ 
-Cervical spatula  used__________________________________________ 
-Alcohol fixed__________________________________________________ 
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-Air dry fixed__________________________________________________ 
-Number of slides______________________________________________ 
(b) Results of Cytology 
i. Normal (PAP I ) ii. Inflammatory/Infection (PAP II) iii. CIN I(PAP III ) 
iv. CIN II ( PAP III ) v. CIN III ( PAP IV ) vi. Invasive ( PAP V ) 
vii. Others ( Specify ) 
______________________________________________________________
______________________________________________________________ 
7. Histopathology Performed ? Yes  or No _________ In certain patients 
where an obvious cervical  lesion is detected , a cervical biopsy will be taken 
for histopathology. 
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
8. SEROLOGY: 
- Serum sample taken____________________________________________ 
- Volume 2-3ml _________________________________________________ 
Results________________________________________________________ 
9.FINAL DIAGNOSIS:____________________________________________ 
B1. Normal ; B2. Cervicitis ; B3. CINI ; B4. CIN II ; B5. CIN III ; 
B6. Squamous Cell Carcinoma ; B7. Adenocarcinoma ; B8. Mixed Ca 
B9. Other Histology; 10. Cancer of the Cervix without histology 
B11.Cancer other than  cervical cancer( specify) 
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
10. OTHER EXAMINATIONS: 
Cancer other than cervical cancer diagnosed by other 
means________________________________________________________
______________________________________________________________
______________________________________________________________ 
(  Clinical ,  Radiological , Immunological , Scan , etc  )    Yes or No 
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If Yes 
Specify________________________________________________________
______________________________________________________________ 
 
11. COMPARATIVE RESULTS  PER  PATIENT: 
Colposcopy:            Positive  (    ), Negative (      ) 
Visual Inspection:   Positive  (     ), Negative (      ) 
Cytology:                Positive  (     ), Negative (      ) 
Biopsy:                   Positive  (     ), Negative (      ) 
Serology:                Positive  (     ), Negative (      ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
